08-02-2009

10/598,789A Yong Chu 07-08-2008

Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:ssptaylc1626

PASSWORD:

TERMI	NAL	(ENT	ER 1	, 2, 3, OR ?):2						
* * *	* *	* *	* *	* Welcome to STN International * * * * * * * * *						
				Welcome to SIN International						
NEWS	1			Web Page for STN Seminar Schedule - N. America						
NEWS	2	JAN	02	STN pricing information for 2008 now available						
NEWS	3	JAN	16	CAS patent coverage enhanced to include exemplified						
				prophetic substances						
NEWS	4	JAN	28	USPATFULL, USPAT2, and USPATOLD enhanced with new						
NEWS	5	JAN	20	custom IPC display formats MARPAT searching enhanced						
NEWS				USGENE now provides USPTO sequence data within 3 days						
NEWS	-		20	of publication						
NEWS	7	JAN	28	TOXCENTER enhanced with reloaded MEDLINE segment						
NEWS	8	JAN	28	MEDLINE and LMEDLINE reloaded with enhancements						
NEWS	9	FEB	08	STN Express, Version 8.3, now available						
NEWS				PCI now available as a replacement to DPCI						
NEWS				IFIREF reloaded with enhancements						
NEWS				IMSPRODUCT reloaded with enhancements						
NEWS	13	FEB	29	WPINDEX/WPIDS/WPIX enhanced with ECLA and current						
				U.S. National Patent Classification						
NEWS	14	MAR	31	IFICDB, IFIPAT, and IFIUDB enhanced with new custom						
				IPC display formats						
NEWS	15	MAR	31	CAS REGISTRY enhanced with additional experimental spectra						
NEWS	16	MAR	31	CA/CAplus and CASREACT patent number format for U.S.						
			-	applications updated						
NEWS	17	MAR	31	LPCI now available as a replacement to LDPCI						
NEWS	18	MAR	31	EMBASE, EMBAL, and LEMBASE reloaded with enhancements						
NEWS	19	APR	04	STN AnaVist, Version 1, to be discontinued						
NEWS	20	APR	15	WPIDS, WPINDEX, and WPIX enhanced with new						
				predefined hit display formats						
NEWS		APR		EMBASE Controlled Term thesaurus enhanced						
NEWS		APR		IMSRESEARCH reloaded with enhancements						
NEWS	23	MAY	30	INPAFAMDB now available on STN for patent family searching						
NEWS	2.4	MAY	3.0	DGENE, PCTGEN, and USGENE enhanced with new homology						
MEMO	24	THE	50	sequence search option						
NEWS	25	JUN	06	EPFULL enhanced with 260,000 English abstracts						
NEWS				KOREAPAT updated with 41,000 documents						
NEWS		JUN		USPATFULL and USPAT2 updated with 11-character						
				patent numbers for U.S. applications						
NEWS	28	JUN	19	CAS REGISTRY includes selected substances from						
				web-based collections						
NEWS	29	JUN	25	CA/CAplus and USPAT databases updated with IPC						
				reclassification data						
NEWS	30	JUN	30	AEROSPACE enhanced with more than 1 million U.S.						

patent records

NEWS 31 JUN 30 EMBASE, EMBAL, and LEMBASE updated with additional options to display authors and affiliated organizations

NEWS 32 JUN 30 STN on the Web enhanced with new STN AnaVist Assistant and BLAST plug-in

NEWS 33 JUN 30 STN AnaVist enhanced with database content from EPFULL

NEWS EXPRESS JUNE 27 08 CURRENT WINDOWS VERSION IS V8.3. AND CURRENT DISCOVER FILE IS DATED 23 JUNE 2008.

NEWS HOURS STN Operating Hours Plus Help Desk Availability

NEWS LOGIN Welcome Banner and News Items

NEWS IPC8 For general information regarding STN implementation of IPC 8

Enter NEWS followed by the item number or name to see news on that specific topic.

All use of STN is subject to the provisions of the STN Customer agreement. Please note that this agreement limits use to scientific research. Use for software development or design or implementation of commercial gateways or other similar uses is prohibited and may result in loss of user privileges and other penalties.

* * * * * * * * * * * * * * * * STN Columbus * * * * * * * * * * * * * * * * * *

FILE 'HOME' ENTERED AT 21:14:57 ON 08 JUL 2008

=> file req

COST IN U.S. DOLLARS SINCE FILE TOTAL. ENTRY SESSION 0.21 0.21

FULL ESTIMATED COST

FILE 'REGISTRY' ENTERED AT 21:15:19 ON 08 JUL 2008 USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT. PLEASE SEE "HELP USAGETERMS" FOR DETAILS. COPYRIGHT (C) 2008 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 7 JUL 2008 HIGHEST RN 1032964-85-4 DICTIONARY FILE UPDATES: 7 JUL 2008 HIGHEST RN 1032964-85-4

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH January 9, 2008.

Please note that search-term pricing does apply when conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and predicted properties as well as tags indicating availability of experimental property data in the original document. For information on property searching in REGISTRY, refer to:

http://www.cas.org/support/stngen/stndoc/properties.html

Uploading C:\Documents and Settings\ychu\Desktop\Case\10598789\10598789A.str





```
10 11 13 14 16 ring nodes:
1 2 3 4 5 6 7 8 9 17 18 19 20 21 22 23 24 25 chain bonds:
8-10 9-13 10-11 10-17 14-16 ring bonds:
1-2 1-6 2-3 3-4 4-5 5-6 5-7 6-9 7-8 8-9 17-18 17-21 18-19 19-20 20-21 20-22 21-25 22-23 23-24 24-25 exact/norm bonds:
1-2 1-6 2-3 3-4 4-5 5-6 5-7 6-9 7-8 8-9 9-13 10-11 10-17 14-16 17-18 17-21 18-19 19-20 20-21 20-22 21-25 22-23 23-24 24-25 exact bonds:
8-10 8-10
```

G2:H,CH,t-Bu


chain nodes :

Match level :

1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom 10:CLASS 11:CLASS 13:CLASS 14:CLASS 15:CLASS 16:CLASS 17:Atom 18:Atom 19:Atom 20:Atom 21:Atom 25:Atom 25:Atom 26:Atom 27:Atom 2

L1 STRUCTURE UPLOADED

=> d L1 HAS NO ANSWERS L1 STR



Structure attributes must be viewed using STN Express query preparation.

=> s 11

SAMPLE SEARCH INITIATED 21:16:01 FILE 'REGISTRY' SAMPLE SCREEN SEARCH COMPLETED -511 TO ITERATE

100.0% PROCESSED 511 ITERATIONS

SEARCH TIME: 00.00.01

22 ANSWERS

FULL FILE PROJECTIONS: ONLINE **COMPLETE** PROJECTED ITERATIONS:

PROJECTED ANSWERS:

BATCH **COMPLETE** 8864 TO 11576 159 TO

L2 22 SEA SSS SAM L1

=> d dscan

'DSCAN' IS NOT A VALID FORMAT FOR FILE 'REGISTRY'

The following are valid formats:

Substance information can be displayed by requesting individual fields or predefined formats. The predefined substance formats are: (RN = CAS Registry Number)

REG - RN

SAM - Index Name, MF, and structure - no RN

FIDE - All substance data, except sequence data

- FIDE, but only 50 names IDE

SQIDE - IDE, plus sequence data

SQIDE3 - Same as SQIDE, but 3-letter amino acid codes are used

SQD - Protein sequence data, includes RN

SQD3 - Same as SQD, but 3-letter amino acid codes are used

SON - Protein sequence name information, includes RN

EPROP - Table of experimental properties

PPROP - Table of predicted properties

Any CA File format may be combined with any substance format to obtain CA references citing the substance. The substance formats must be cited first. The CA File predefined formats are:

ABS -- Abstract

APPS -- Application and Priority Information

BIB -- CA Accession Number, plus Bibliographic Data

CAN -- CA Accession Number

CBIB -- CA Accession Number, plus Bibliographic Data (compressed)

IND -- Index Data

IPC -- International Patent Classification

PATS -- PI, SO

STD -- BIB, IPC, and NCL

IABS -- ABS, indented, with text labels

IBIB -- BIB, indented, with text labels

ISTD -- STD format, indented

OBIB ----- AN, plus Bibliographic Data (original)

OIBIB ----- OBIB, indented with text labels

SBIB ----- BIB, no citations

SIBIB ----- IBIB, no citations

The ALL format gives FIDE BIB ABS IND RE, plus sequence data when it is available.

The MAX format is the same as ALL.

The IALL format is the same as ALL with BIB ABS and IND indented, with text labels.

For additional information, please consult the following help messages:

HELP DFIELDS -- To see a complete list of individual display fields. HELP FORMATS -- To see detailed descriptions of the predefined formats. ENTER DISPLAY FORMAT (IDE):end

=> d scan

L2 22 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN

IN 1H-Indole-2-carboxamide, 6-(diethylamino)-N-[2-[(4,5,8,8a-tetrahydro-7-methyl-4-oxocyclopropa[3,4]pyrrolo[3,2-e]indazol-2(1H)-yl)carbonyl]-1H-indol-5-yl]-

MF C33 H31 N7 O3

CI COM

PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):end

=>

Uploading C:\Documents and Settings\ychu\Desktop\Case\10598789\10598789B.str

```
chain nodes :
10 11 13 14 16 31 32 38 39 42 43 44 45 50
ring nodes :
1 2 3 4 5 6 7 8 9 17 18 19 20 21 22 23 24 25 26 27 28 29 30
33 34 35 36 37
chain bonds :
8-10 9-13 10-11 10-17 14-16 14-50 30-31 31-32 37-38 38-39 42-43 43-44
44-45
ring bonds :
1-2 1-6 2-3 3-4 4-5 5-6 5-7 6-9 7-8 8-9 17-18 17-21 18-19 19-20 20-21
20-22 21-25 22-23 23-24 24-25 26-27 26-30 27-28 28-29 29-30 33-34 33-37
34-35 35-36
36-37
exact/norm bonds :
1-2 1-6 2-3 3-4 4-5 5-6 5-7 6-9 7-8 8-9 9-13 10-11 10-17 14-16 14-50
17-18 17-21 18-19 19-20 20-21 20-22 21-25 22-23 23-24 24-25 26-27 26-30
27-28 28-29
29-30 31-32 33-34 33-37 34-35 35-36 36-37 38-39 42-43 44-45
exact bonds :
8-10 30-31 37-38 43-44
```

G2:H,CH,t-Bu

G3:[*1],[*2],[*3]

```
Match level:
1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom 10:CLASS
11:CLASS 13:CLASS 14:CLASS 15:CLASS 16:CLASS 17:Atom 18:Atom 19:Atom 20:Atom 21:Atom 22:Atom 23:Atom 25:Atom 26:Atom 27:Atom 28:Atom 29:Atom 30:Atom 31:CLASS 32:CLASS 33:Atom 36:Atom 37:Atom 38:CLASS 39:CLASS 42:CLASS 43:CLASS 45:CLASS 45:CLASS 45:CLASS
```

L3 STRUCTURE UPLOADED

=> d L3 HAS NO ANSWERS L3 STR

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

Structure attributes must be viewed using STN Express query preparation.

=> s 13.....

SAMPLE SEARCH INITIATED 21:24:39 FILE 'REGISTRY' SAMPLE SCREEN SEARCH COMPLETED -354 TO ITERATE

100.0% PROCESSED 354 ITERATIONS

13 ANSWERS

SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE **COMPLETE** BATCH **COMPLETE** PROJECTED ITERATIONS: 5952 TO 8208

1.4

13 SEA SSS SAM L3

=> d scan

13 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN L4

Cyclopropa[c]pyrrolo[3,2-e]indol-4(5H)-one, 2-[[5-[(aminocarbonyl)amino]-

476

1H-indol-2-yl]carbonyl]-1,2,8,8a-tetrahydro-7-methyl- (9CI)

44 TO

MF C22 H19 N5 O3

PROJECTED ANSWERS:

PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):2

L413 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN

Acetamide, N-[2-[[(1S)-1-[(1R)-1-chloroethyl]-1,2-dihydro-5-IN (phenylmethoxy)-3H-benz[e]indol-3-y1]carbony1]-1H-indol-5-y1]-2(dimethylamino)-MF C34 H33 C1 N4 O3

Absolute stereochemistry. Rotation (+).

PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

- L4 13 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN
- IN Carbamic acid, dimethyl-, (1S)-1-(chloromethyl)-2,3-dihydro-3-[[5-[(1H-indol-2-ylcarbonyl)amino)-1H-indol-2-yl]carbonyl]-1H-benz[e]indol-5-yl ester (9C1)
- MF C34 H28 C1 N5 O4

Absolute stereochemistry. Rotation (+).

PAGE 1-B

-NMe2

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):end

=> s 113 full L5 11 LL3

=> s 13 full

FULL SEARCH INITIATED 21:25:56 FILE 'REGISTRY' FULL SCREEN SEARCH COMPLETED -7282 TO ITERATE

100.0% PROCESSED 7282 ITERATIONS SEARCH TIME: 00.00.01

343 ANSWERS

TOTAL

191.54

1.6 343 SEA SSS FUL L3

=> file caplus

COST IN U.S. DOLLARS

SINCE FILE ENTRY SESSION 191.33

FULL ESTIMATED COST

FILE 'CAPLUS' ENTERED AT 21:26:04 ON 08 JUL 2008 USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT. PLEASE SEE "HELP USAGETERMS" FOR DETAILS. COPYRIGHT (C) 2008 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 8 Jul 2008 VOL 149 ISS 2 FILE LAST UPDATED: 7 Jul 2008 (20080707/ED)

Caplus now includes complete International Patent Classification (IPC) reclassification data for the second quarter of 2008.

Effective October 17, 2005, revised CAS Information Use Policies apply. They are available for your review at:

http://www.cas.org/legal/infopolicy.html

=> s 16.... 183 L6

=> d ibib abs hitstr 175-183

L7 ANSWER 175 OF 183 CAPLUS COPYRIGHT 2008 ACS on STN ACCESSION NUMBER: 1988:124054 CAPLUS Full-text

DOCUMENT NUMBER: 108:124054

ORIGINAL REFERENCE NO.: 108:20145a,20148a

TITLE: Mutagenicity of the antitumor antibiotic CC-1065 and its analogs in mammalian (V79) cells and bacteria AUTHOR(S): Harbach, Philip R.; Zimmer, David M.; Mazurek, John

H.; Bhuvan, Bijov K.

Dep. Pathol. Toxicol. Res., Upjohn Co., Kalamazoo, MI, CORPORATE SOURCE:

SOURCE:

49001, USA Cancer Research (1988), 48(1), 32-6 CODEN: CNREA8; ISSN: 0008-5472

DOCUMENT TYPE: LANGUAGE:

Journal

English

AB The mutagenicity for V79 cells (6-thioguanine resistance) and Salmonella (histidine auxotrophy or azaquanine resistance) of selected analogs of CC-1065 (I) was compared to DNA-binding activity and the structure-activity relationship was detd. CC-1065, U-62,736, U-66,866, U-66,694, U-67,786, and U-68,415 all have an A segment with an intact cyclopropyl group and different B segments. The cyclopropyl group is absent from U-66,226 and U-63,360. Elimination of the cyclopropyl ring diminished the cytotoxic and mutagenic potency of the compds. such that U-63,360 was nearly 3 orders of magnitude less potent than CC-1065 in V79 cells. For the compds. with an intact cyclopropyl group, the order of cytotoxic and mutagenic potency (molar basis) in V79 cells generally correlated with binding to calf thymus DNA, and increased with the length of the B segment. Thus, the order of cytotoxicity was CC-1065 > U-68,415 > U-66,694 > U-66,866 > U-62,736. U-67,786 cell outside this pattern since it was more cytotoxic and mutagenic than U-66,694, although it was of a similar size and had similar DNA-binding activity. These results show that an electrophilic C afforded by an intact cyclopropyl group of this type is necessary but not sufficient to account for the high cytotoxic and mutagenic potency of CC-1065 and U-68,415. The size and characteristics of the B segment also affect the potency. At an equitoxic (10 or 50% LD) dose, an inverse relationship exists between cytotoxic and mutagenic potency such that at the 50% LD, the least cytotoxic compd. (U-62,736) was more mutagenic than the most cytotoxic compd. (CC-1065). Apparently, the more cytotoxic analogs are less mutagenic (at an equitoxic dose) because they may have greater structure-directed binding to less mutable DNA sites in the minor groove.


104713-40-8

RL: BIOL (Biological study)

(cytotoxic and mutagenic activities of, DNA binding in, structure in relation to)

104713-40-8 CAPLUS RN CN

1H-Indole-2-carboxamide, N-[2-[(4.5.8.8a-tetrahydro-7-methyl-4oxocyclopropa[c]pyrrolo[3,2-e]indol-2(1H)-y1)carbonyl]-1H-indol-5-y1]-(CA INDEX NAME)



L7 ANSWER 176 OF 183 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 1988:94431 CAPLUS Full-text

DOCUMENT NUMBER: 108:94431

ORIGINAL REFERENCE NO.: 108:15531a,15534a

TITLE: Stereoelectronic factors influencing the biological activity and DNA interaction of synthetic antitumor

agents modeled on CC-1065
AUTHOR(S): Warpehoski, M. A.; Gebhard, I.; Kellv, R. C.; Krueger,

W. C.; Li, L. H.; McGovren, J. P.; Prairie, M. D.; Wicnienski, N.; Wierenga, W.

CORPORATE SOURCE: Res. Lab., Upjohn Co., Kalamazoo, MI, 49001, USA

Journal of Medicinal Chemistry (1988), 31(3), 590-603

CODEN: JMCMAR; ISSN: 0022-2623

DOCUMENT TYPE: Journal LANGUAGE: English

OTHER SOURCE(S): CASREACT 108:94431

O T

SOURCE .

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

- AB The synthesis, physicochem. properties, and biol. activities of 21 novel spiro cyclopropyl compds., e.g. I [R = H, SO2Ph, CO2CMe3, COMe, substituted (indol-2-yl)carbonyl], prepd. by intramol. cyclopropanation of pyrroloindoles II (RI = PhCH2, R2 = SO2CF3; R1 = R2 = H), are described. Many I are more effective than the antitumor antibiotic CC-1065 (III) against murine tumors. In particular, IV exhibits high activity and potency. Structure-activity anal. supports a mol. mechanism of biol. action involving hydrophobic interaction of the drug with DNA and acid-catalyzed alkylation of DNA.
- II 101134-50-3P RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(prepn. and mesylation of)

RN 101134-50-3 CAPLUS

CN 1H-Indole-2-carboxamide, N-[2-[[1,6-dihydro-1-(hydroxymethyl)-8-methyl-5-(phenylmethoxy)benzo[1,2-b:4,3-b']dipyrrol-3(2H)-yl]carbonyl]-1H-indol-5-yl]-(9C1) (CA INDEX NAME)

IT 112090-00-3P 112090-01-4P

RL: SPN (Synthetic preparation); PREP (Preparation) (prepn. of)

RN 112090-00-3 CAPLUS

CN Benzo[1,2-b:4,3-b']dipyrrole-1-methanol, 3-[[5-[(aminocarbonyl)amino]-1H-indol-2-yl]oarbonyl]-1,2,3,6-tetrahydro-5-hydroxy-8-methyl- (9CI) (CA INDEX NAME)

RN 112090-01-4 CAPLUS

CN Benzo[1,2-b:4,3-b')dipyrrole-1-methanol, 3-[[5-[(aminocarbonyl)amino]-1H-indol-2-yl]carbonyl]-1,2,3,6-tetrahydro-5-hydroxy-8-methyl-, monomethyl ether (9CI) (CA INDEX NAME)

CM 1

CRN 112090-00-3

CMF C22 H21 N5 O4

CRN 67-56-1 CMF C H4 O

H3C-OH

IT 101134-80-9P 101151-46-6P 101151-47-7P 104713-40-8P

RL: SPN (Synthetic preparation); PREP (Preparation)
(prepn., antitumor activity, induced CD, and kinetics of ring cleavage of)

RN 101134-80-9 CAPLUS

CN 1H-Indole-2-carboxamide, 5-(benzoylamino)-N-[2-[(4,5,8,8a-tetrahydro-7-methyl-4-oxocyclopropa[c]pyrrolo[3,2-e]indol-2(1H)-yl)carbonyl]-1H-indol-5-yl)- (CA INDEX NAME)

RN 101151-46-6 CAPLUS

RN 101151-47-7 CAPLUS

CN 1H-Indole-2-carboxamide, 5-[(aminocarbonyl)amino]-N-[2-[(4,5,8,8a-tetrahydro-7-methyl-4-oxocyclopropa(c]pyrrolo[3,2-e]indol-2(1H)-yl)carbonyl]-1H-indol-5-yl]- (CA INDEX NAME)

RN 104713-40-8 CAPLUS

CN 1H-Indole-2-carboxamide, N-[2-|(4,5,8,8a-tetrahydro-7-methyl-4oxocyclopropa|c|pyrrolo[3,2-e|indol-2(1H)-yl)carbonyl]-1H-indol-5-yl]-(CA INDEX NAME)

IT 101134-61-6P 101134-62-7P 101134-63-8P 101134-65-0P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(prepn., debenzylation, and intramol. cyclopropanation of)

RN 101134-61-6 CAPLUS

CN 1H-Indole-2-carboxamide, N-[2-[1,6-dihydro-8-methyl-1-[(methylsulfonyl)oxy|methyl]-5-(phenylmethoxy)benzo[1,2-b:4,3-b']dipyrrol-3(2H)-yl]carbonyl]-1H-indol-5-yl]- (9CI) (CA INDEN NAME)

RN 101134-62-7 CAPLUS

CN 1H=Indole=2-carboxamide, 5-(benzoylamino)-N-[2-[[1,6-dihydro-8-methyl-1[[(methylsulfonyl)oxy]methyl]-5-(phenylmethoxy)benzo[1,2-b:4,3-b']dipyrrol3(2H)-yl]carbonyl]-1H=indol-5-yl]- (9CI) (CA INDEX NAME)

RN 101134-63-8 CAPLUS

CN Benzo[1,2-b:4,3-b']dipyrrole-1-methanol, 3-[[5-[(aminocarbonyl)amino]-1H-indol-2-yl]carbonyl]-1,2,3,6-tetrahydro-8-methyl-5-[phenylmethoxy)-, methanesulfonate (ester) (9C1) (CA INDEX NAME)

RN 101134-65-0 CAPLUS

CN 1H-Indole-2-carboxamide, 5-[(aminocarbonyl)amino]-N-[2-[[1,6-dihydro-8-methyl-1-[[(methylsuifonyl)oxy]methyl]-5-(phenylmethoxy)benzo[1,2-b:4,3-b']dipyrrol-3(2H)-yl]carbonyl]-1H-indol-5-yl]- (9C1) (CA INDEX NAME)

L7 ANSWER 177 OF 183 CAPLUS COPYRIGHT 2008 ACS on STN ACCESSION NUMBER: 1988:87686 CAPLUS Full-text DOCUMENT NUMBER: 108:87686

ORIGINAL REFERENCE NO.: 108:14287a,14290a

TITLE: Effects of U-71.

Effects of U-71,184 and several other CC-1065 analogs on cell survival and cell cycle of Chinese hamster ovary cells

Adams, Earl G.; Badiner, Gloria J.; Bhuyan, Bijoy K. AUTHOR(S):

CORPORATE SOURCE: Upjohn Co., Kalamazoo, MI, 49001, USA Cancer Research (1988), 48(1), 109-16 SOURCE:

CODEN: CNREA8; ISSN: 0008-5472

DOCUMENT TYPE: Journal LANGUAGE: English

The effects of several analogs of CC-1065 on inhibition of CHO cell survival, cell progression, and their phase-specific toxicity are reported. CC-1065, U-66,664, U-66,819, U-66,694, and U-71,184 all have a left hand segment with an intact cyclopropyl group but have different tail segments. Lethality of these compds. after 2 h drug exposure was in the following order (50% lethal concn. in nM in parentheses): CC-1065 (0.06) > U-71,184 (1.3) > U-66,694 (3.2) > U-68,819 (171) > U-66,664 (>1200). In general, these compds. did not inhibit progression from G1 to S but slowed progression through S and blocked cells in G2-M. The phase-specific toxicity of U-71,184 and U-66,694 was different from that of CC-1065, CC-1065 was most cytotoxic to cells in M and early G1 and toxicity decreased as cells entered late G1 and S. In contrast, U-66,694 and U-71,184 were most toxic to cells in late G1. The biochem. and cellular effects of U-71.184 were then studied in detail since it was the most active among these analogs. After a 2-h exposure to 3 ng/mL U-71,184, 90% cell kill or growth inhibition was obsd., whereas 100 ng/mL was needed for similar inhibition of DNA and RNA synthesis. This discrepancy between the doses suggested that inhibition of nucleic acid synthesis may not be causally related to lethality. Further studies showed that when drug was removed after 2 h exposure, DNA synthesis continued to be inhibited, whereas RNA and protein synthesis reached levels higher than the control. Therefore, it is likely that at cytotoxic doses the low level of inhibition of DNA synthesis combined with the stimulation of RNA and protein synthesis leads to unbalanced growth and

cell death. 104713-39-5, U-71185 RL: PRP (Properties)

(cytotoxicity of, cell cycle in relation to)

RN 104713-39-5 CAPLUS

CN 1H-Indole-2-carboxamide, N-[2-[[(7bS,8aR)-4,5,8,8a-tetrahydro-7-methyl-4oxocyclopropa[c]pyrrolo[3,2-e]indol-2(1H)-yl]carbonyl]-1H-indol-5-yl]-(CA INDEX NAME)

Absolute stereochemistry. Rotation (-).

L7 ANSWER 178 OF 183 CAPLUS COPYRIGHT 2008 ACS on STN ACCESSION NUMBER: 1987:597901 CAPLUS Full-text DOCUMENT NUMBER: 107:197901

ORIGINAL REFERENCE NO.: 107:31735a,31738a

TITLE: Coupling of cyclopropapyrroloindole (CPI) derivatives. The preparation of CC-1065, ent-CC-1065, and analogs

AUTHOR(S): Kelly, Robert C.; Gebhard, Ilse; Wicnienski, Nancy; Aristoff, Paul A.; Johnson, Paul D.; Martin, David G.

CORPORATE SOURCE: Cancer and Viral Dis. Res., Upjohn Co., Kalamazoo, MI,

49001, USA

SOURCE: Journal of the American Chemical Society (1987),

109(22), 6837-8

CODEN: JACSAT; ISSN: 0002-7863
DOCUMENT TYPE: Journal

LANGUAGE: Journal English

OTHER SOURCE(S): CASREACT 107:197901

GI

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB CC-1065 (I, R = R1) and its analogs I (R = pentyl, 2-indolyl, R2, X = NH, O) were prepd. from the pyrroloindole II (R3 = OH, R4 = H, R5 = CH2Ph) via II (R3 = Cl, R4 = C02CMe3, R5 = H), II (R3 = Cl, R4 = R5 = H), and II (R3 = Cl, R4 = COR, R5 = H). Ent-CC-1065 was similarly prepd. and had an ED50 against leukemia L1210 of 4.5 times. 10-12 q/mL.

IT 108833-15-4P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(prepn. and chlorination of)

RN 108833-15-4 CAPLUS

CN IH-Indole-2-carboxamide, N-[2-[1],6-dihydro-8-methyl-1-[(methylsulfonyl)oxy]methyl]-5-(phenylmethoxy)benzo[1,2-b:4,3-b']dipyrrol-3(2H)-yl]carbonyl]-1H-indol-5-yl]-, (S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

IT 110314-46-0P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(prepn. and cyclopropanation of)

RN 110314-46-0 CAPLUS

CN 1H-Indole-2-carboxamide, N-[2-[[1-(chloromethyl)-1,6-dihydro-5-hydroxy-8methylbenzo[1,2-b:4,3-b']dipyrrol-3(2H)-yl]carbonyl]-1H-indol-5-yl]-, (S)-(9C1) (CA INDEX NAME)

Absolute stereochemistry.

- IT 110314-44-8P
 - RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
- (prepn. and hydrogenolysis of)
- RN 110314-44-8 CAPLUS
- CN 1H-Indole-2-carboxamide, N-[2-[[1-(chloromethyl)-1,6-dihydro-8-methyl-5-(phenylmethoxy)benzo[1,2-b:4,3-b']dipyrrol-3(2H)-yl]carbonyl]-1H-indol-5-yl]-, (S)- (9C1) (CA INDEX NAME)

Absolute stereochemistry.

- IT 101222-80-4P
 - RL: SPN (Synthetic preparation); PREP (Preparation)
- (prepn. of) RN 101222-80-4 CAPLUS
- CN 1H-Indole-2-carboxamide, N-[2-[[(7bR,8aS)-4,5,8,8a-tetrahydro-7-methyl-4-oxocyclopropa[c]pyrrolo[3,2-e]indol-2(1H)-yl]carbonyl]-1H-indol-5-yl]-(CA INDEX NAME)

Absolute stereochemistry. Rotation (+).

L7 ANSWER 179 OF 183 CAPLUS COPYRIGHT 2008 ACS on STN 1987:423139 CAPLUS Full-text ACCESSION NUMBER:

DOCUMENT NUMBER: 107:23139

ORIGINAL REFERENCE NO.: 107:3903a,3906a

TITLE: Total synthesis of U-71184, a potent new antitumor

agent modeled on CC-1065

AUTHOR(S):

Warpehoski, M. A. CORPORATE SOURCE: Upjohn Co., Kalamazoo, MI, 49001, USA

SOURCE: Tetrahedron Letters (1986), 27(35), 4103-6

CODEN: TELEAY; ISSN: 0040-4039

Journal DOCUMENT TYPE:

LANGUAGE: English

OTHER SOURCE(S): CASREACT 107:23139

AB

U-71184 (I), a highly potent analog of novel antitumor antibiotic CC-1065, involves the unmasking of a p-hydroxyphenethyl mesylate, which undergoes facile intramol. elimination to afford the reactive cyclopropylspirocyclohexadienone. Its enantiomer, U-71185, was also prepd. I had antitumor activity comparable to that of CC-1065 without the delayed toxicity, but U-71185 was inactive.

тт 101222-80-4P, U-71184 104713-39-5P, U-71185

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)

(prepn. and antitumor activity of)

101222-80-4 CAPLUS RN

CN 1H-Indole-2-carboxamide, N-[2-[[(7bR,8aS)-4,5,8,8a-tetrahydro-7-methyl-4oxocyclopropa[c]pyrrolo[3,2-e]indol-2(1H)-y1]carbony1]-1H-indol-5-y1]-(CA INDEX NAME)

Absolute stereochemistry. Rotation (+).

RN 104713-39-5 CAPLUS

CN 1H-Indole-2-carboxamide, N-[2-[[(7b5,8aR)-4,5,8,8a-tetrahydro-7-methyl-4-oxocyclopropa[c]pyrrolo[3,2-e]indol-2(1H)-yl]carbonyl]-1H-indol-5-yl]-(CA INDEX NAME)

Absolute stereochemistry. Rotation (-).

IT 108833-16-5P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(prepn. and cyclopropanation of)

RN 108833-16-5 CAPLUS

CN 1H-Indole-2-carboxamide, N-[2-[[1,6-dihydro-5-hydroxy-8-methyl-1-[[(methylsulfonyl)oxy]methyl]benzo[1,2-b:4,3-b']dipyrrol-3(2H)-

yl]carbonyl]-1H-indol-5-yl]-, (S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

IT 108833-15-4P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(prepn. and debenzylation of)

RN 108833-15-4 CAPLUS

CN 1H-Indole-2-carboxamide, N-[2-[[1,6-dihydro-8-methyl-1[((methylsulfonyl)oxy|methyl]-5-(phenylmethoxy)benzo[1,2-b:4,3-b']dipyrrol3(2H)-yl]carbonyl]-1H-indol-5-yl]-, (S)- (901) (CA INDEX NAME)

Absolute stereochemistry.

IT 108859-64-9P

RI: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent) (prepn. and mesylation of)

RN 108859-64-9 CAPLUS

CN 1H-Indole-2-carboxamide, N-[2-[[1,6-dihydro-1-(hydroxymethyl)-8-methyl-5-(phenylmethoxy)benzo[1,2-b:4,3-b']dipyrrol-3(2H)-yl]carbonyl]-1H-indol-5-yl]-, (S)- (9C1) (CA INDEX NAME)

Absolute stereochemistry.

L7 ANSWER 180 OF 183 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 1987:12465 CAPLUS Full-text
DOCUMENT NUMBER: 106:12465

OCUMENI NUMBER: 106:12465

ORIGINAL REFERENCE NO.: 106:2037a,2040a

TITLE: L1210 cell growth inhibition, DNA synthesis

inhibition, and DNA binding properties of CC-1065

analogs

AUTHOR(S): Krueger, W. C.; Prairie, M. D.; Wallace, T. L.;

Moscowitz, A.; Li, L. H.
CORPORATE SOURCE: Upjohn Co., Kalamazoo, MI

CORPORATE SOURCE: Upjohn Co., Kalamazoo, MI, USA
SOURCE: Recent Adv. Chemother., Proc. Int. Congr. Chemother.,

14th (1985), Volume Anticancer Sect. 1, 572-3.

Editor(s): Ishiqami, Joji. Univ. Tokyo Press: Tokyo,

Japan.

CODEN: 55GNAX

DOCUMENT TYPE: Conference; General Review

LANGUAGE: English

GI

The biol. and biochem. activities of some analogs of the highly potent but toxic antitumor antibiotic ML-1065 (I) [69866-21-3] are compared to their DNA

Ι

binding properties. In general, the binding affinity correlates with potency in the P388 activity and the degree of inhibition of L1210 cell growth and macromol. synthesis.

IT 101222-80-4 104713-33-5

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); BIOL (Biological study)

(antitumor activity of and DNA binding by and DNA formation response to)

RN 101222-80-4 CAPLUS

AB

CN 1H-Indole-2-carboxamide, N-[2-[[(7bR,8aS)-4,5,8,8a-tetrahydro-7-methyl-4-oxocyclopropa[c]pyrrolo[3,2-e]indol-2(1H)-yl]carbonyl]-1H-indol-5-yl]-(CA INDEX NAME)

Absolute stereochemistry. Rotation (+).

RN 104713-39-5 CAPLUS

CN IH-Indole-2-carboxamide, N-[2-[[(7b5,8aR)-4,5,8,8a-tetrahydro-7-methyl-4-oxocyclopropa[c]pyrrolo[3,2-e]indol-2(1H)-yl]carbonyl]-1H-indol-5-yl]-(CA INDEX NAME)

Absolute stereochemistry. Rotation (-).

L7 ANSWER 181 OF 183 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 1987:291 CAPLUS Full-text

DOCUMENT NUMBER: 106:291 ORIGINAL REFERENCE NO.: 106:55a

TITLE: N-2-substituted tetrahydro-4-

oxocyclopropa[c]pyrrolo[3,2-e]indoles: novel

anticancer agents modeled on CC-1065
AUTHOR(S): Warpehoski, M. A.; Kelly, R. C.; McGovren, J. P.;

.UTHOR(S): Warpenoski, M. A.; Kelly, R. Wierenga, W.

CORPORATE SOURCE: Upjohn Co., Kalamazoo, MI, USA

SOURCE: Recent Adv. Chemother., Proc. Int. Congr. Chemother.,

14th (1985), Volume Anticancer Sect. 1, 570-1.

Editor(s): Ishigami, Joji. Univ. Tokyo Press: Tokyo,

Japan.

CODEN: 55GNAX DOCUMENT TYPE: Conference

LANGUAGE: English

GI

AB The antitumor activity of ML-1065 (I) [69866-21-3] and its analogs II (R = Me, 2-quinolinyl, 2-pyrrolyl, 2-indolyl, etc.) is described. Analogs with acyl, aroyl, and heteroaroyl substituents on N-2 of II had generated 2 highly active subgroups differentiated by DNA binding. Several DNA-binding analogs

exhibited similar potency to I but significantly improved antitumor activity (murine and human) with an absence of delayed lethality.

104713-40-8

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(antitumor activity of)

104713-40-8 CAPLUS RN

CN 1H-Indole-2-carboxamide, N-[2-[(4,5,8,8a-tetrahydro-7-methyl-4oxocyclopropa[c]pyrrolo[3,2-e]indol-2(1H)-yl)carbonyl]-1H-indol-5-yl]-(CA INDEX NAME)

ANSWER 182 OF 183 CAPLUS COPYRIGHT 2008 ACS on STN 1986:564557 CAPLUS Full-text ACCESSION NUMBER:

DOCUMENT NUMBER:

AUTHOR(S):

DOCUMENT TYPE:

105:164557 ORIGINAL REFERENCE NO.: 105:26357a,26360a

TITLE:

Antitumor activity and biochemistry of novel analogs

of the antibiotic, CC-1065

Wierenga, W.; Bhuyan, B. K.; Kelly, R. C.; Krueger, W. C.; Li, L. H.; McGovren, J. P.; Swenson, D. H.;

Ι

Warpehoski, M. A.

CORPORATE SOURCE: Upjohn Co., Kalamazoo, MI, 49001, USA

SOURCE: Advances in Enzyme Regulation (1986), 25, 141-55

CODEN: AEZRA2; ISSN: 0065-2571

Journal; General Review

LANGUAGE: English

NCONH2

AB A discussion on the in vitro and in vivo antitumor activities of ML-1065 (I) [69866-21-3] and its analogs is presented. The effects of these compds. on

macromol. (DNA, protein, and RNA) biosynthesis and cell cycle are discussed. A review of previous work is included.

101222-80-4 104713-39-5 104713-40-8

RL: PRP (Properties)

(antitumor activity and biochem. effects of, in humans and lab. animals)

RN 101222-80-4 CAPLUS

1H-Indole-2-carboxamide, N-[2-[[(7bR,8aS)-4,5,8,8a-tetrahydro-7-methyl-4oxocyclopropa[c]pyrrolo[3,2-e]indol-2(1H)-yl]carbonyl]-1H-indol-5-yl]-(CA INDEX NAME)

Absolute stereochemistry. Rotation (+).


104713-39-5 CAPLUS RN

CN 1H-Indole-2-carboxamide, N-[2-[[(7bS,8aR)-4,5,8,8a-tetrahydro-7-methyl-4oxocyclopropa[c]pyrrolo[3,2-e]indol-2(1H)-yl]carbonyl]-1H-indol-5-yl]-(CA INDEX NAME)

Absolute stereochemistry. Rotation (-).

104713-40-8 CAPLUS RN

CN 1H-Indole-2-carboxamide, N-[2-[(4,5,8,8a-tetrahydro-7-methyl-4oxocyclopropa[c]pyrrolo[3,2-e]indol-2(1H)-yl)carbonyl]-1H-indol-5-yl]-(CA INDEX NAME)



L7 ANSWER 183 OF 183 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 1986:148641 CAPLUS Full-text

DOCUMENT NUMBER: 104:148641

ORIGINAL REFERENCE NO.: 104:23517a,23520a TITLE: Analogs of antibioti

TITLE: Analogs of antibiotic CC-1065
INVENTOR(S): Kelly, Robert Charles; Warpehosk

INVENTOR(S): Kelly, Robert Charles; Warpehoski, Martha Ann; Wierenga, Wendell

PATENT ASSIGNEE(S): Upjohn Co. , USA

SOURCE: Eur. Pat. Appl., 96 pp.

CODEN: EPXXDW DOCUMENT TYPE: Patent

LANGUAGE: English
FAMILY ACC. NUM. COUNT: 2

PATENT INFORMATION:

| PATENT | NO. | K | IND | DATE | | API | PLICATION N | DATE | |
|-------------|-----------|-------|-------|-------|------|--------|-------------|------|----------|
| | | | | | | | | | |
| EP 154 | 445 | | A1 | 1985 | 0911 | EP | 1985-3011 | 25 | 19850220 |
| EP 154 | 445 | 1 | 31 | 1989 | 0531 | | | | |
| R: | BE, CH, | DE, F | R, GB | , IT, | LI, | NL, SI | Ε | | |
| US 491 | 2227 | | A. | 1990 | 0327 | US | 1986-8943 | 14 | 19860807 |
| JP 082 | 25573 | 1 | A | 1996 | 0903 | JP | 1995-3316 | 40 | 19951220 |
| PRIORITY AP | PLN. INFO | . : | | | | US | 1984-58183 | 36 A | 19840221 |
| | | | | | | US | 1985-69436 | 53 A | 19850124 |
| | | | | | | CA | 1985-47393 | 17 A | 19850208 |
| | | | | | | ZA | 1985-1093 | A | 19850213 |
| | | | | | | EP | 1985-30112 | 25 A | 19850220 |
| | | | | | | JP | 1985-31663 | 2 A | 19850221 |

GI

AB Title compds. I and II (R1, R2, R3 = H, alkyl, phenyl; R4 = H, acyl; R5 = acyl; R6 = halo, substituted sulfonyloxy; R7 = Me, substituted Me) and their salts, useful as UV light absorbents, bactericides, and antitumors were prepd.

Thus, II (R1 = R2 = R3 = H, R5 = mesyl, R7 = PhCH2) was N-demesylated, N-acetylated, O-mesylated, O-debenzylated, and cyclized to give I (RI = R2 = R3 = H, R4 = Ac). The latter compd. showed cytotoxic activity against murine L1210 tumor cells at 0.0048 .mu.q/mL.

IT 101134-75-2P 101134-79-6P 101134-83-2P

101134-84-39

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(prepn. and cyclization of)

RN 101134-75-2 CAPLUS

CN 1H-Indole-2-carboxamide, N-[2-[[1,6-dihydro-5-hydroxy-8-methyl-1-[((methylsulfonyl)oxy]methyl]benzo[1,2-b:4,3-b']dipyrrol-3(2H)yl]carbonyl]-H-indol-5-yl]- (9CI) (CA INDEX NAME)

RN 101134-79-6 CAPLUS

CN 1H-Indole-2-carboxamide, 5-(benzoylamino)-N-[2-[[1,6-dihydro-5-hydroxy-8-methyl-1-[[(methylsulfonyl)oxy]methyl]benzo[1,2-b:4,3-b']dipyrrol-3(2H)-yl]carbonyl]-1H-indol-5-yl]- (9CI) (CA INDEX NAME)

RN 101134-83-2 CAPLUS

CN Benzo[1,2-b:4,3-b']dipyrrole-1-methanol, 3-[[5-[(aminocarbonyl)amino]-1H-indol-2-yl]carbonyl]-1,2,3,6-tetrahydro-5-hydroxy-8-methyl-, alpha.-methanesulfonate (9CT) (CA INDEX NAME)

RN 101134-84-3 CAPLUS

CN 1H-Indole-2-carboxamide, 5-[(aminocarbonyl)amino]-N-[2-[[1,6-dihydro-5-hydroxy-8-methyl-1-[[(methylsuffonyl)oxy]methyl]benzo[1,2-b:4,3-b']dibyrrol-3(2H)-yl]carbonyl]-1H-indol-5-yl]-(9C1) (CA INDEX NAME)

IT 101134-61-6P 101134-62-7P 101134-63-8P

101134-65-0P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(prepn. and debenzylation of)

RN 101134-61-6 CAPLUS

RN 101134-62-7 CAPLUS

CN 1H-Indole-2-carboxamide, 5-(benzoylamino)-N-[2-[1,6-dihydro-8-methyl-1-[(methylsulfonyl)oxy]methyl]-5-(phenylmethoxy)benzo[1,2-b:4,3-b']dipyrrol-3(2H)-yl]carbonyl]-1H-indol-5-yl]- (9CI) (CA INDEX NAME)

RN 101134-63-8 CAPLUS

CN Benzo[1,2-b:4,3-b']dipyrrole-1-methanol, 3-[[5-[(aminocarbonyl)amino]-1H-indol-2-yl]carbonyl]-1,2,3,6-tetrahydro-8-methyl-5-(phenylmethoxy)-, methanesulfonate (ester) (9C1) (CA INDEX NAME)

RN 101134-65-0 CAPLUS

CN 1H-Indole-2-carboxamide, 5-{(aminocarbonyl)amino]-N-[2-[[1,6-dihydro-8-methyl-1-[[(methylsulfonyl)oxy]methyl]-5-(phenylmethoxy)benzo[1,2-b:4,3-b')dipyrrol-3(2H)-yl]carbonyl]-1H-indol-5-yl]- (SCI) (CA INDEX NAME)

IT 101134-50-3P 101134-52-5P 101134-53-6P 101151-43-3P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(prepn. and mesylation of)

RN 101134-50-3 CAPLUS

CN 1H-Indole-2-carboxamide, N-[2-[[1,6-dihydro-1-(hydroxymethyl)-8-methyl-5-(phenylmethoxy)benzo[1,2-b:4,3-b']dipyrrol-3(2H)-yl]carbonyl]-1H-indol-5-yl]-(9C1) (CA INDEX NNB)

RN 101134-52-5 CAPLUS

CN 1H-Indole-2-carboxamide, 5-(benzoylamino)-N-[2-[1],6-dihydro-1-(hydroxymethyl)-8-methyl-5-(phenylmethoxy)benzo[1,2-b:4,3-b']dipyrrol-3(2H)-yl]carbonyl]-Ha-indol-5-yl]- (9CI) (CA INDEX NAME)

RN 101134-53-6 CAPLUS

CN 1H-Indole-2-carboxamide, 5-[(aminocarbonyl)amino]-N-[2-[[1,6-dihydro-1-(hydroxymethyl)-8-methyl-5-(phenylmethoxy)benzo[1,2-b:4,3-b']dipyrrol-3(2H)-yl]carbonyl]-1H-indol-5-yl]- (9CI) (CA INDEX NAME)

RN 101151-43-3 CAPLUS

CN Benzo[1,2-b:4,3-b']dipyrrole-1-methanol, 3-[[5-[(aminocarbonyl)amino]-1H-indol-2-yl]carbonyl]-1,2,3,6-tetrahydro-8-methyl-5-(phenylmethoxy)- (9CI) (CA INDEX NAME)

IT 101134-80-9P 101151-46-6P 101151-47-7P

101222-80-4F 104713-40-8P

RL: SPN (Synthetic preparation); PREP (Preparation)

(prepn. of, as antitumor and antibiotic)

RN 101134-80-9 CAPLUS

CN 1H-Indole-2-carboxamide, 5-(benzoylamino)-N-[2-[(4,5,8,8a-tetrahydro-7-methyl-4-oxocyclopropa(c)pyrrolo[3,2-e]indol-2(1H)-yl)carbonyl]-1H-indol-5-yl]- (CA INDEX NAME)

RN 101151-46-6 CAPLUS

CN Cyclopropa[c]pyrrolo[3,2-e]indol-4(5H)-one, 2-[[5-[(aminocarbonyl)amino]-H-indol-2-yl]carbonyl]-1,2,8,8a-tetrahydro-7-methyl- (9CI) (CA INDEX NAME)

RN 101151-47-7 CAPLUS

CN 1H-Indole-2-carboxamide, 5-{(aminocarbony1)amino]-N-[2-[(4,5,8,8a-tetrahydro-7-methy1-4-oxocyclopropa|c|pyrrolo[3,2-e]indol-2(1H)-y1)carbony1-1H-indol-5-y1]- (CA INDEX NAME)

RN 101222-80-4 CAPLUS

CN 1H-Indole-2-carboxamide, N-[2-[[(7bR,8aS)-4,5,8,8a-tetrahydro-7-methyl-4-oxocycloppa|c|pyrrolo[3,2-e]indol-2(1H)-yl]carbonyl]-1H-indol-5-yl]-(CA INDEX NAME)

Absolute stereochemistry. Rotation (+).

RN 104713-40-8 CAPLUS

CN 1H-Indole-2-carboxamide, N-[2-[(4,5,8,8a-tetrahydro-7-methyl-4oxocyclopropa[c]pyrrolo[3,2-e]indol-2(1H)-yl)carbonyl]-1H-indol-5-yl]-(CA INDEX NAME)

=> file reg COST IN U.S. DOLLARS

FULL ESTIMATED COST

SINCE FILE TOTAL ENTRY SESSION 56.73 248.27 CA SUBSCRIBER PRICE

FILE 'REGISTRY' ENTERED AT 21:35:30 ON 08 JUL 2008 USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT. PLEASE SEE "HELP USAGETERMS" FOR DETAILS. COPYRIGHT (C) 2008 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 7 JUL 2008 HIGHEST RN 1032964-85-4
DICTIONARY FILE UPDATES: 7 JUL 2008 HIGHEST RN 1032964-85-4

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH January 9, 2008.

Please note that search-term pricing does apply when conducting ${\tt SmartSELECT}$ searches.

REGISTRY includes numerically searchable data for experimental and predicted properties as well as tags indicating availability of experimental property data in the original document. For information on property searching in REGISTRY, refer to:

http://www.cas.org/support/stngen/stndoc/properties.html

=>

Uploading C:\Documents and Settings\ychu\Desktop\Case\10598789\10598789C.str



```
Chain nodes:
10 11 13 14 16 31 32 38 39 43
ring nodes:
1 2 3 4 5 6 7 8 9 17 18 19 20 21 22 23 24 25 26 27 28 29 30
33 34 35 36 37 45 46 47 48
chain bonds:
8-10 9-13 10-11 10-17 14-16 14-43 30-31 31-32 37-38 38-39
ring bonds:
1-2 1-6 2-3 3-4 4-5 5-6 5-7 6-9 7-8 8-9 17-18 17-21 18-19 19-20 20-21
20-22 21-25 22-23 22-45 23-24 23-48 24-25 26-27 26-30 27-28 28-29 29-30
33-34 33-37 33-37
34-35 35-36 36-37 45-46 46-47 47-48
exact/norw bonds:
```

```
26-27 26-30
27-28 28-29 29-30 31-32 33-34 33-37 34-35 35-36 36-37 38-39 45-46 46-47
47-48
exact bonds :
8-10 30-31 37-38
isolated ring systems :
containing 26 : 33 :
G2:H,CH,t-Bu
G3:[*1],[*2]
Match level :
1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom 10:CLASS
11:CLASS 13:CLASS 14:CLASS 15:CLASS 16:CLASS 17:Atom 18:Atom 19:Atom
20:Atom 21:Atom 22:Atom
23:Atom 24:Atom 25:Atom 26:Atom 27:Atom 28:Atom 29:Atom 30:Atom 31:CLASS
32:CLASS 33:Atom
34:Atom 35:Atom 36:Atom 37:Atom 38:CLASS 39:CLASS 43:CLASS 45:Atom 46:Atom
47:Atom
48:Atom
L8
       STRUCTURE UPLOADED
=> d
L8 HAS NO ANSWERS
L8
              STR
* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *
Structure attributes must be viewed using STN Express query preparation.
=> s 18
SAMPLE SEARCH INITIATED 21:36:19 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED -
                                  228 TO ITERATE
100.0% PROCESSED
                  228 ITERATIONS
                                                            1 ANSWERS
SEARCH TIME: 00.00.01
FULL FILE PROJECTIONS: ONLINE **COMPLETE**
                      BATCH
                            **COMPLETE**
PROJECTED ITERATIONS:
                           3655 TO
                                    5465
PROJECTED ANSWERS:
                              1 TO
                                        8.0
             1 SEA SSS SAM L8
1.9
=> d scan
    1 ANSWERS
              REGISTRY COPYRIGHT 2008 ACS on STN
L9
TN
    methyl-1H-pyrrol-2-yl]carbonyl]amino]-1-methyl-1H-pyrrol-2-
    v1|carbonv1|amino|-1-methv1-1H-pvrro1-2-v1|carbonv1|amino|-1-methv1-1H-
    pyrrol-2-yl]carbonyl]amino]-1-oxobutyl]amino]-N-[5-[[[2-[(9,9a-dihydro-4-
    oxo-1H-benzo[e]cvcloprop[c]indol-2(4H)-v1)carbonv1]-1H-indol-5-
    yl]amino]carbonyl]-1-methyl-1H-pyrrol-3-yl]-1-methyl-
```

PAGE 1-A

PAGE 2-A

39 ANSWERS

-7.20

0.00



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

ALL ANSWERS HAVE BEEN SCANNED

=> s 18 full

FULL SEARCH INITIATED 21:37:05 FILE 'REGISTRY'

FULL SCREEN SEARCH COMPLETED - 4127 TO ITERATE

100.0% PROCESSED 4127 ITERATIONS SEARCH TIME: 00.00.01

L10 39 SEA SSS FUL L8

=> file caplus

CA SUBSCRIBER PRICE

COST IN U.S. DOLLARS
SINCE FILE TOTAL
ENTRY SESSION
179.28 427.55

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)
SINCE FILE
TOTAL
ENTRY SESSION
ENTRY SESSION

FILE 'CAPLUS' ENTERED AT 21:37:13 ON 08 JUL 2008
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2008 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 8 Jul 2008 VOL 149 ISS 2 FILE LAST UPDATED: 7 Jul 2008 (20080707/ED)

Caplus now includes complete International Patent Classification (IPC) reclassification data for the second quarter of 2008.

Effective October 17, 2005, revised CAS Information Use Policies apply. They are available for your review at:

http://www.cas.org/legal/infopolicy.html

=> s 110

16 L10

=> d ibib abs hitstr tot

L11 ANSWER 1 OF 16 CAPLUS COPYRIGHT 2008 ACS on STN ACCESSION NUMBER: 2008:492970 CAPLUS Full-text

TITLE: Sequence-specific alkylation by Y-shaped and tandem

hairpin pyrrole-imidazole polyamides

AUTHOR(S): Sasaki, Shunta; Bando, Toshikazu; Minoshima, Masafumi;

Shinohara, Ken-ichi; Sugiyama, Hiroshi/
CORPORATE SOURCE: Department of Chemistry, Kyoto University,

Kitashirakawa-Oiwaketyo, Sakyo, Kyoko, 606-8502, Japan

SOURCE: Chemistry--A European Journal (2008), 14(3), 864-870 CODEN: CEUJED; ISSN: 0947-6539

PUBLISHER: Wiley-VCH Verlag GmbH & Co. KGaA

DOCUMENT TYPE: Journal LANGUAGE: English

LANGUAGE: English

B To extend the target DNA sequence length of the hairpin pyrrole-imidazole (PyIm) polyamide 1, the authors designed and syyfhesized Y-shaped and tandem
hairpin Py-Tim polyamides 2 and 3, which possess 1-(chloromethyl)-5-hydroxy1,2-dihydro-3H-benz[e]indole (seco-CBI) as DNA-alkylating moieties. Highresoln. denaturing polyacylamide gel electrophoresis by using 5'-Texas-Redlabeled 465 base pair (bp) DNA fragments revealed that conjugates 2 and 3
alkylated the adenine of the target DNA sequences at nanomolar concns.

Conjugate 2 alkylated adenine N3 at the 3' end of two 8 bp match sequences,
5'-AA- TAACCA-3' (site A) and 5'-AAATTC-CA-3' (site C), while conjugate 3
recognized one 10 bp match sequence, 5'-TAGATAACCA-3' (site A) in the 465 bp
DNA fragments. These results demonstrate that seco-CBI conjugates of Y-shaped
and tandem hairpin polyamides have extended their target alkylation sequences.

IT INDEXING IN PROGRESS
IT 1032252-71-3P 1032252-73-5P 1032252-75-7P

RL: BSU (Biological study, unclassified); PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent)

(solid-phase prepn. of tandem hairpin pyrrole-imidazole polyamides, evaluation of their DNA-alkylating capabilities and cytotoxicity in human cancer cell lines)

RN 1032252-71-3 CAPLUS

CN INDEX NAME NOT YET ASSIGNED

RN 1032252-73-5 CAPLUS

CN INDEX NAME NOT YET ASSIGNED

Absolute stereochemistry.

PAGE 1-B

RN 1032252-75-7 CAPLUS

CN INDEX NAME NOT YET ASSIGNED

Absolute stereochemistry.



REFERENCE COUNT: 29 THERE ARE 29 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L11 ANSWER 2 OF 16 CAPLUS COPYRIGHT 2008 ACS on STN 2008:339576 CAPLUS <u>Full-text</u> ACCESSION NUMBER:

DOCUMENT NUMBER: 148:555820

TITLE: Requirement of .beta.-alanine components in

sequence-specific DNA alkylation by pyrrole-imidazole

conjugates with seven-base pair recognition

AUTHOR(S): Bando, Toshikazu; Minoshima, Masafumi; Kashiwazaki, Gengo; Shinohara, Ken-ichi; Sasaki, Shunta; Fujimoto,

Jun; Ohtsuki, Akimichi; Murakami, Masataka; Nakazono, Satomi; Sugivama, Hiroshi

Department of Chemistry, Graduate School of Science,

CORPORATE SOURCE: Kvoto University, Sakvo, Kvoto, 606-8501, Japan

Bioorganic & Medicinal Chemistry (2008), 16(5), SOURCE: 2286-2291

CODEN: BMECEP; ISSN: 0968-0896

PUBLISHER: Elsevier Ltd. DOCUMENT TYPE: Journal

LANGUAGE: English

AB To investigate the effect of incorporation of .beta.-alanine in alkylating Nmethylpyrrole (Py)-N-methylimidazole (Im) polyamide, seco-CBI conjugates 2-8 were synthesized by an Fmoc solid-phase method and subsequent coupling with an alkylating moiety. DNA-alkylating activities of conjugates 2-8 were evaluated by high-resoln. denaturing gel electrophoresis with 202-base pair (bp) DNA fragments. Alkylation by conjugates 2 and 3, which have antiparallel pairings of .beta.-alanine (.beta.) opposite .beta. (.beta./.beta.) and Py/.beta., occurred mainly at the adenine (A) of the matching sequences, 5'-AGCTCC-3' (site 1) and 5'-AGCACC-3' (site 3). However, conjugate 4, with .beta./Py, did not show any DNA-alkylating activities. Similarly, conjugate 5, which possessed a Py/Py pair, weakly alkylated the matching sites at micromolar concns. Conjugates 6 and 7, which possessed .beta./.beta. and Py/.beta. pairs, resp., alkylated at the A of the matching sequences, 5'-ACTACC-3' (site 2) and 5'-ACAACC-3' (site 4). In contrast, conjugated 8, with a Py/Py pair, showed lower activity and less alkylated DNA at sites 2 and 4 with mismatched alkylation at site 1 at a higher concn. than that of 6 and 7. These results demonstrate that incorporation of .beta.-alanine is required for the sequencespecific alkylation by seco-CBI Py-Im conjugates with a seven-base pair sequence.

865113-72-0P 1026780-43-2P 1026780-50-6P IΤ 1026780-52-8P 1026780-53-9P 1026780-54-0P RL: BSU (Biological study, unclassified); PRP (Properties); RCT

(Reactant); SPN (Synthetic preparation); BIOL (Biological study); PREP

(Preparation); RACT (Reactant or reagent)
 (requirement of .beta.-alanine components in sequence-specific DNA
 alkylation by pyrrole-imidazole conjugates with seven-base pair
 recognition)

RN 865113-72-0 CAPLUS

CN | H-Imidazole-2-carboxamide, 4-[[[4-(acetylamino)-1-methyl-1H-imidazol-2-yl]carbonyl]amino]-N-[5-[[[5-[[[4-[12-[[15-[[[2-[1-(chloromethyl)-1,2-dihydro-5-hydroxy-3H-benz [e]indol-3-yl]amino]-arbonyl]-1H-indol-5-yl]amino]carbonyl]-1-methyl-1H-pyrrol-3-yl]amino]carbonyl]-1-methyl-1H-imidazol-4-yl]amino]-arbonyl]-1-methyl-1H-pyrrol-3-yl]amino]carbonyl]-1-methyl-1H-pyrrol-3-yl]amino]carbonyl]-1-methyl-1H-pyrrol-3-yl]amino]carbonyl]-1-methyl-1H-pyrrol-3-yl]amino]carbonyl]-1-methyl-1H-pyrrol-3-yl]amino]carbonyl]-1-methyl-1H-pyrrol-3-yl]amino]carbonyl]-1-methyl-1H-pyrrol-3-yl]amino]carbonyl]-1-methyl-1H-pyrrol-3-yl]amino]carbonyl]-1-methyl-1H-pyrrol-3-yl]amino]carbonyl]-1-methyl-1H-pyrrol-3-yl]amino]carbonyl]-1-methyl-1H-pyrrol-3-yl]amino]carbonyl]-1-methyl-1H-pyrrol-3-yl]amino]carbonyl]-1-methyl-1H-pyrrol-3-yl]amino]carbonyl]-1-methyl-1H-pyrrol-3-yl]amino]carbonyl]-1-methyl-1H-pyrrol-3-yl]amino]carbonyl]-1-methyl-1H-pyrrol-3-yl]amino]carbonyl]-1-methyl-1H-pyrrol-3-yl]amino]carbonyl]-1-methyl-1H-pyrrol-3-yl]amino]carbonyl]-1-methyl-1H-pyrrol-3-yl]amino]carbonyl]-1-methyl-1H-pyrrol-3-yl]-1-methyl-1H-pyrrol-3-yl]-1-methyl-1H-pyrrol-3-yl]-1-methyl-1H-pyrrol-3-yl]-1-methyl-1H-pyrrol-3-yl]-1-methyl-1H-pyrrol-3-yl]-1-methyl-1H-pyrrol-3-yl]-1-methyl-1H-pyrrol-3-yl]-1-methyl-1H-pyrrol-3-yl]-1-methyl-1H-pyrrol-3-yl]-1-methyl-1H-pyrrol-3-yl]-1-methyl-1H-pyrrol-3-yl]-1-methyl-1H-pyrrol-3-yl]-1-methyl-1H-pyrrol-3-yl]-1-methyl-1H-pyrrol-3-yl]-1-methyl-1H-pyrrol-3-yl]-1-methyl-1H-pyrrol-3-yl]-1-methyl-1H-pyrrol-3-yl]-1-methyl-1H-pyrrol-3-yl]-1-methyl-1H-pyrrol-3-yl]-1-methyl-1H-pyrrol-3-yl]-1-methyl-1H-pyrrol-3-yl]-1-methyl-1H-pyrrol-3-yl]-1-methyl-1H-pyrrol-3-yl]-1-methyl-1H-pyrrol-3-yl]-1-methyl-1H-pyrrol-3-yl]-1-methyl-1H-pyrrol-3-yl]-1-methyl-1H-pyrrol-3-yl]-1-methyl-1H-pyrrol-3-yl]-1-methyl-1H-pyrrol-3-yl]-1-methyl-1H-pyrrol-3-yl]-1-methyl-1H-pyrrol-3-yl]-1-methyl-1H-pyrrol-3-yl]-1-methyl-1H-pyrrol-3-yl]-1-methyl-1H-pyrrol-3-yl]-1-methyl-1H-pyrrol-3-yl]-1-methyl-1-methyl-1-methyl-1-methyl-1-methyl-1-methyl-1-methyl-1-methyl-

PAGE 2-A

PAGE 1-A

RN 1026780-48-2 CAPLUS

CN INDEX NAME NOT YET ASSIGNED

PAGE 4-A

RN 1026780-52-8 CAPLUS

CN INDEX NAME NOT YET ASSIGNED

PAGE 1-A

RN 1026780-53-9 CAPLUS

CN INDEX NAME NOT YET ASSIGNED

RN 1026780-54-0 CAPLUS CN INDEX NAME NOT YET ASSIGNED

PAGE 4-A

REFERENCE COUNT:

THERE ARE 20 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L11 ANSWER 3 OF 16 CAPLUS COPYRIGHT 2008 ACS on STN ACCESSION NUMBER: 2007:662474 CAPLUS Full-text

20

DOCUMENT NUMBER: 147:323219

TITLE: Molecular design of DNA alkylating pyrrole-imidazole

polyamides with longer recognition sequence
AUTHOR(S): Minoshima, Masafumi; Sasaki, Shunta; Shinohara,

Ken-ichi; Shimizu, Tatsuhiko; Bando, Toshikazu;

Sugiyama, Hiroshi

CORPORATE SOURCE: Department of Chemistry, Graduate School of Science, Kyoto University, Kitashirakawa-oiwakecho, Sakyo,

Kyoto, 606-8502, Japan

SOURCE: Nucleic Acids Symposium Series (2006), (50), 165-166

CODEN: NASSCJ URL: http://nass.oxfordjournals.org/content/vol50/issu

el/index.dtl

PUBLISHER: Oxford University Press

DOCUMENT TYPE: Journal; (online computer file)
LANGUAGE: English

LANGUAGE: EIIG

AB The sequence-specificity, and DNA alkylating activity of the conjugate 1, which consists of N-methylpyrrole (Py)-N-methylimidazole (Im) polyamides, 1- (chloromethyl)-5-hydroxy-1,2-dihydro-3H-benz[e]indole (seco-CBI) with indole

linker, were investigated in the absence or presence of partner Py-Im polyamide 2. High-resoln. denaturing PAGE showed that the specificity of DNA alkylation by 1 modulated in the presence of partner 2. We found that sequence-specific DNA alkylation by 1 and 2 with 10 base pair (bp) match recognition sequence through heterodimer formation. This result indicates one possibility of DNA alkylation with longer recognition sequence by different two mols.

IT 947725-88-7

CN

RL: BUU (Biological use, unclassified); RCT (Reactant); BIOL (Biological study); RACT (Reactant or reagent); USES (Uses)

(DNA alkylating agent; sequence-specific alkylation of DNA with pyrrole-imidazole polyamide seco-CBI conjugate in presence of partner polyamide)

RN 947726-88-7 CAPLUS

H-Imidazole-2-carboxamide, 4-[[[4-(acetylamino)-1-methyl-1H-imidazol-2-yl]carbonyl]amino]-N-[5-[[[3-[[5-[[2-[[1-(chloromethyl]-1,2-dihydro-5-hydroxy-3H-benz[e]indol-3-yl]carbonyl]-1H-indol-5-yl]amino]carbonyl]-1-methyl-1H-pyrrol-3-yl]amino]carbonyl]-1-methyl-1H-imidazol-4-yl]amino]-3-oxopropyl]amino]carbonyl]-1-methyl-1H-pyrrol-3-yl]-1-methyl- (CA INDEX NAME)

PAGE 3-A

REFERENCE COUNT:

THERE ARE 10 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L11 ANSWER 4 OF 16 CAPLUS COPYRIGHT 2008 ACS on STN ACCESSION NUMBER: 2007:662469 CAPLUS Full-text

10

DOCUMENT NUMBER: 148:182769 TITLE: Synthesis a

TITLE: Synthesis and evaluation of sequence-specific DNA alkylating agents: effect of alkylation subunits AUTHOR(S): Shimizu, Tatsuhiko; Sasaki, Shunta; Minoshima, Masafumi; Shinohara, Ken-ichi; Bando, Toshikazu;

Sugiyama, Hiroshi

CORPORATE SOURCE: Department of Chemistry, Graduate School of Science, Kyoto University, Kitashirakawa Oiwakecho, Sakyo-ku,

Kyoto, 606-8502, Japan

SOURCE: Nucleic Acids Symposium Series (2006), (50), 155-156 CODEN: NASSCJ

URL: http://nass.oxfordjournals.org/content/vol50/issu
el/index.dt1

PUBLISHER: Oxford University Press

DOCUMENT TYPE: Journal; (online computer file)
LANGUAGE: English

LANGUAGE:

AB We have demonstrated that hairpin pyrrole (Py)-imidazole (Im) polyamide-CBI conjugates selectively alkylate predetd. sequences. In this study, we investigated the effect of alkylation subunits, for example conjugates 1-4

with three types of DNA alkylating units, and Py-Im polyamides with indole linker. Conjugate 3 and 4 selectively alkylated the predetd. sequences as described previously, while conjugates 1 and 2 alkylate at mismatched sites.

IT 265113-72-0 1004312-35-9

RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(sequence-specific DNA alkylating agents as antitumor drugs with improved selectivity)

RN 865113-72-0 CAPLUS

CN 1H-Imidazole-2-carboxamide, 4-[[[4-(acetylamino)-1-methyl-1H-imidazol-2-yl]carbonyl]amino]-N-[5-[[[5-[[[4-[l]2-[[l5-[[[2-[l]4-chloromethyl]-1,2-dihydro-5-hydroxy-3H-benz[e]indol-3-yl]carbonyl]-1H-indol-5-

yl]amino]carbonyl]-1-methyl-1H-pyrrol-3-yl]amino]carbonyl]-1-methyl-1H-

imidazol-4-yl]amino]-4-oxobutyl]amino]carbonyl]-1-methyl-1H-pyrrol-3yl]amino]carbonyl]-1-methyl-1H-pyrrol-3-yl]-1-methyl- (CA INDEX NAME)

PAGE 3-A

- RN 1004312-35-9 CAPLUS
- CN 1H-Imidazole-2-carboxamide, 4-(acetylamino)-N-[2-[[[5-[[[5-[[[5-[[[5-[[[5-
 - [[[2-[[1-(chloromethyl)-1,2-dihydro-5-hydroxy-3H-benz[e]indol-3yl]carbonyl]-1H-indol-5-yl]amino]carbonyl]-1-methyl-1H-pyrrol-3-

 - yl]amino]carbonyl]-1-methyl-1H-pyrrol-3-yl]amino]-4oxobutyl]amino]carbonyl]-1-methyl-1H-pyrrol-3-yl]amino]carbonyl]-1-methyl-
 - 1H-pyrrol-3-yl]amino]carbonyl]-1-methyl-1H-imidazol-4-yl]-1-methyl- (CA INDEX NAME)



REFERENCE COUNT:

THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L11 ANSWER 5 OF 16 CAPLUS COPYRIGHT 2008 ACS on STN ACCESSION NUMBER: 2007:662447 CAPLUS Full-text

DOCUMENT NUMBER: 147:316628

TITLE: The biological impact of sequence-specific DNA

alkylation by pyrroleimidazole polyamides Sasaki, Shunta; Minoshima, Masafumi; Shimizu, AUTHOR(S):

Tatsuhiko; Fujimoto, Jun; Shinohara, Ken-ichi; Bando, Toshikazu; Sugiyama, Hiroshi

Department of Chemistry, Graduate School of Science, CORPORATE SOURCE: Kvoto University, Kitashirakawa Oiwake, Sakyo-ku,

Kyoto, 606-8502, Japan Nucleic Acids Symposium Series (2006), (50), 111-112 SOURCE:

CODEN: NASSCJ

URL: http://nass.oxfordjournals.org/content/vol50/issu e1/index.dtl

PUBLISHER: Oxford University Press

DOCUMENT TYPE: Journal; (online computer file) English

LANGUAGE:

We have developed a series of novel DNA alkylating polyamides possessing indole linkers. Investigations using high-resoln, gel electrophoresis revealed that the indole linked Py-Im polyamide alkylated at A of a targeted nine base pair matching sequence. Evaluation in human cancer cell lines revealed that the indole linked Py-Im polyamides have strong cytotoxicities. Furthermore, we showed that alkylation of the template strand of the coding region by these polyamides causes effective gene silencing.

893419-09-5P 947597-79-7P 947597-85-5P

947597-99-1P

RL: BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)

(biol. impact of sequence-specific DNA alkylation by pyrroleimidazole polyamides)

893419-09-5 CAPLUS

RN CN 1H-Imidazole-2-carboxamide, 4-[[[4-(acetylamino)-1-methyl-1H-imidazol-2-[[[2-[[1-(chloromethv1)-1,2-dihvdro-5-hvdroxv-3H-benz[e]indol-3yl]carbonyl]-1H-indol-5-yl]amino]carbonyl]-1-methyl-1H-pyrrol-3-yl]amino]-3-oxopropyllaminolcarbonyll-1-methyl-1H-pyrrol-3-yllaminolcarbonyll-1methyl-1H-pyrrol-3-yl]amino]carbonyl]-1-methyl-1H-pyrrol-3-yl]amino]-4oxobutyl]amino]carbonyl]-1-methyl-1H-imidazol-4-yl]amino]carbonyl]-1methy1-1H-pyrro1-3-y1]amino]carbony1]-1-methy1-1H-pyrro1-3-y1]amino]-3oxopropv1laminolcarbonv1l-1-methv1-1H-pvrro1-3-v11-1-methv1- (CA INDEX NAME)

RN 947597-79-7 CAPLUS CN 1H-Imidazole-2-carbo

1H-Imidazole-2-carboxamide, 4-[[[4-[[[4-([[4-([actylamino)-1-methyl-1H-pyrrol-2-yl]carbonyl]amino]-1-methyl-1H-imidazol-2-yl]carbonyl]amino]-1-methyl-1H-pyrrol-2-yl]carbonyl]amino]-N-[4-[[2-[[[5-[[2-[[1-([chloromethyl)-1,2-dihydro-5-hydroxy-3H-benz[e]indol-3-yl]carbonyl]-1H-indol-5-yl]amino]carbonyl]-1-methyl-1H-pyrrol-3-yl]amino]carbonyl]-1-methyl-1-methyl-1-[-indolazol-2-yl]amino]carbonyl]-1-methyl-1-[-(CA INDEX NAME)

PAGE 3-A

RN 947597-85-5 CAPLUS

CN 1H-Imidazole-2-carboxamide, 4-[[[4-[[[4-[[[4-(acetylamino)-1-methyl-1H-imidazol-2-y1]carbonyl]amino]-1-methyl-1H-pyrrol-2-y1]carbonyl]amino]-1-methyl-1H-pyrrol-2-y1]carbonyl]amino]-1-(chloromethyl)-1,2-dihydro-5-hydroxy-3H-benz[e]indol-3-y1]carbonyl]-1H-indol-5-y1]amino]carbonyl]-1-methyl-1H-jyrrol-3-y1]amino]carbonyl]-1-methyl-1H-inidazol-4-y1]amino]-4-oxobutyl]-1-methyl-1 (G. INDEX NAME)

RN 947597-99-1 CAPLUS

CN 1H-Imidazole-2-carboxamide, 4-[[[4-(acetylamino)-1-methyl-1H-imidazol-2-yl]carbonyl]amino]-N-[5-[[[2-[[14-[2-[[15-[[[2-[1-(chloromethyl)-1,2-dihydro-5-hydroxy-3H-benz[e]indol-3-yl]carbonyl]-1H-imidal-5-yl]amino]carbonyl]-1-methyl-1H-pyrrol-3-yl]amino]carbonyl]-1-methyl-1H-jmidazol-4-yl]amino]-ad-oxobutyl]amino[arbonyl]-1-methyl-1H-jmidazol-4-yl]amino]carbonyl]-1-methyl-1H-jmidazol-4-yl]amino]carbonyl]-1-methyl-1H-jmidazol-3-yl]-1-methyl-1H-jmidazol-4-yl]amino]carbonyl]-1-methyl-1H-jmidazol-3-yl]-1-methyl-1H-jmidazol-3-yl]-1-methyl-1H-jmidazol-3-yl]-1-methyl-1H-jmidazol-3-yl]-1-methyl-1H-jmidazol-3-yl]-1-methyl-1H-jmidazol-3-yl]-1-methyl-1H-jmidazol-3-yl]-1-methyl-1H-jmidazol-3-yl]-1-methyl-1H-jmidazol-3-yl]-1-methyl-1-methyl-1-methyl-1-methyl-1-methyl-1-methyl-1-methyl-1-methyl-1-methyl-1-methyl-1-methyl-1-methyl-1-methyl-1-methyl-1-methyl-1-methyl-1-methyl-1-methyl-1-methyl-1-methyl-1-methyl-1-methyl-1-methyl-1-methyl-1-methyl-1-methyl-1-methyl-1-methyl-1-methyl-1-methyl-1-methyl-1-methyl-1-methyl-1-methyl-1-methyl-1-methyl-1-methyl-1-methyl-1-methyl-1-methyl-1-methyl-1-methyl-1-methyl-1-methyl-1-methyl-1-methyl-1-methyl-1-methyl-1-methyl-1-methyl-1-methyl-1-methyl-1-methyl-1-methyl-1-methyl-1-methyl-1-methyl-1-methyl-1-methyl-1-methyl-1-methyl-1-methyl-1-methyl-1-methyl-1-methyl-1-methyl-1-methyl-1-methyl-1-methyl-1-methyl-1-methyl-1-methyl-1-methyl-1-methyl-1-methyl-1-methyl-1-methyl-1-methyl-1-methyl-1-methyl-1-methyl-1-methyl-1-methyl-1-methyl-1-methyl-1-methyl-1-methyl-1-methyl-1-methyl-1-methyl-1-methyl-1-methyl-1-methyl-1-methyl-1-methyl-1-methyl-1-methyl-1-methyl-1-methyl-1-methyl-1-methyl-1-methyl-1-methyl-1-methyl-1-methyl-1-methyl-1-methyl-1-methyl-1-methyl-1-methyl-1-methyl-1-methyl-1-methyl-1-methyl-1-methyl-1-methyl-1-methyl-1-methyl-1-methyl-1-methyl-1-methyl-1-methyl-1-methyl-1-methyl-1-methyl-1-methyl-1-methyl-1-methyl-1-methyl-1-methyl-1-methyl-1-methyl-1-methyl-1-methyl-1-methyl-1-methyl-1-methyl-1-methyl-1-methyl-1-methyl-1-methyl-1-methyl-1-methyl-1-methyl-1-methyl-1-methyl-1-methyl-1-m

PAGE 3-A

IT 947597-72-0P 947597-93-5P

RL: SPN (Synthetic preparation); PREP (Preparation)

(biol. impact of sequence-specific DNA alkylation by pyrroleimidazole polyamides)

RN 947597-72-0 CAPLUS

CN IH-Imidazole-2-carboxamide, 4-[[4-[[4-[[4-(acetylamino)-1-methyl-1H-pyrrol-2-y1]carbonyl]amino]-1-methyl-1H-pyrrol-2-y1]carbonyl]amino]-N-[4-[[2-[[5-[[12-([1-(chloromethyl)-1,2-dihydro-5-hydroxy-3H-benz[e]indol-3-y1]carbonyl]-1H-indol-5-y1]amino]carbonyl]-1-methyl-1H-pyrrol-3-y1]amino]carbonyl]-1-methyl-1H-indiazol-4-y1]amino]-4-xobutyl]-1-methyl- (CA INDEX NAME)

RN 947597-93-5 CAPLUS

CN

1H-Imidazole-2-carboxamide, 4-(acetylamino)-N-[5-[[[5-[[2-[[[4-[[5-[[5-[[2-[1-(chloromethyl)-1,2-dihydro-5-hydroxy-3H-benz[e]indol-3-yl]carbonyl]-1H-indol-5-yl]amino]carbonyl]-1-methyl-1H-pyrrol-3-yl]amino]carbonyl]-1-methyl-1H-pyrrol-3-yl]amino]carbonyl]-1-methyl-1H-pyrrol-3-yl]amino]carbonyl]-1-methyl-1H-pyrrol-3-yl]amino]carbonyl]-1-methyl-1H-pyrrol-3-yl]amino]carbonyl]-1-methyl-1H-pyrrol-3-yl]-1-methyl-1H-pyrrol-3-yl]-1-methyl-1H-pyrrol-3-yl]-1-methyl-1H-pyrrol-3-yl]-1-methyl-1H-pyrrol-3-yl]-1-methyl-1H-pyrrol-3-yl]-1-methyl-1H-pyrrol-3-yl]-1-methyl-1H-pyrrol-3-yl]-1-methyl-1H-pyrrol-3-yl]-1-methyl-1H-pyrrol-3-yl]-1-methyl-1H-pyrrol-3-yl]-1-methyl-1H-pyrrol-3-yl]-1-methyl-1H-pyrrol-3-yl]-1-methyl-1H-pyrrol-3-yl]-1-methyl-1H-pyrrol-3-yl]-1-methyl-1H-pyrrol-3-yl]-1-methyl-1H-pyrrol-3-yl]-1-methyl-1H-pyrrol-3-yl]-1-methyl-1H-pyrrol-3-yl]-1-methyl-1H-pyrrol-3-yl]-1-methyl-1H-pyrrol-3-yl]-1-methyl-1H-pyrrol-3-yl]-1-methyl-1H-pyrrol-3-yl]-1-methyl-1H-pyrrol-3-yl]-1-methyl-1H-pyrrol-3-yl]-1-methyl-1H-pyrrol-3-yl]-1-methyl-1H-pyrrol-3-yl]-1-methyl-1H-pyrrol-3-yl]-1-methyl-1H-pyrrol-3-yl]-1-methyl-1H-pyrrol-3-yl]-1-methyl-1H-pyrrol-3-yl]-1-methyl-1H-pyrrol-3-yl]-1-methyl-1H-pyrrol-3-yl]-1-methyl-1H-pyrrol-3-yl]-1-methyl-1H-pyrrol-3-yl]-1-methyl-1H-pyrrol-3-yl]-1-methyl-1H-pyrrol-3-yl]-1-methyl-1H-pyrrol-3-yl]-1-methyl-1H-pyrrol-3-yl]-1-methyl-1H-pyrrol-3-yl]-1-methyl-1H-pyrrol-3-yl]-1-methyl-1H-pyrrol-3-yl]-1-methyl-1H-pyrrol-3-yl]-1-methyl-1H-pyrrol-3-yl]-1-methyl-1H-pyrrol-3-yl]-1-methyl-1H-pyrrol-3-yl]-1-methyl-1H-pyrrol-3-yl]-1-methyl-1H-pyrrol-3-yl]-1-methyl-1H-pyrrol-3-yl]-1-methyl-1H-pyrrol-3-yl]-1-methyl-1H-pyrrol-3-yl]-1-methyl-1H-pyrrol-3-yl]-1-methyl-1H-pyrrol-3-yl]-1-methyl-1H-pyrrol-3-yl]-1-methyl-1H-pyrrol-3-yl]-1-methyl-1H-pyrrol-3-yl]-1-methyl-1H-pyrrol-3-yl]-1-methyl-1H-pyrrol-3-yl]-1-methyl-1H-pyrrol-3-yl]-1-methyl-1H-pyrrol-3-yl]-1-methyl-1H-pyrrol-3-yl]-1-methyl-1H-pyrrol-3-yl]-1-methyl-1H-pyrrol-3-yl]-1-methyl-1H-pyrrol-3-yl]-1-methyl-1H-pyrrol-3-yl]-1-methyl-1H-pyrrol-3-yl]-1-methyl-1H-pyrrol-3

PAGE 3-A

REFERENCE COUNT: THERE ARE 10 CITED REFERENCES AVAILABLE FOR THIS 10 RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L11 ANSWER 6 OF 16 CAPLUS COPYRIGHT 2008 ACS on STN ACCESSION NUMBER: 2007:662248 CAPLUS Full-text

DOCUMENT NUMBER: 147:315627

TITLE: Sequence-specific gene silencing by alkylating Py-Im

polyamide

AUTHOR(S): Shinohara, Ken-ichi; Sasaki, Shunta; Bando, Toshikazu;

Sugivama, Hiroshi

CORPORATE SOURCE: Graduate School of Science, Kyoto University,

Kitashirakawa Oiwakecho, Sakyo-ku, Kyoto, 606-8502,

Japan

Nucleic Acids Symposium Series (2005), (49), 75-76 SOURCE: CODEN: NASSCJ

URL: http://nass.oxfordjournals.org/content/vol49/issu

e1/index.dtl

PUBLISHER: Oxford University Press

DOCUMENT TYPE: Journal; (online computer file)

LANGUAGE: English AB We have demonstrated that hairpin pyrrole (Py)-imidazole (Im) polyamide-CPI conjugates selectively induced luciferase gene silencing by sequence-specific alkylation of the coding region. Recently, we developed a new type of Py-Im polyamide CBI conjugate with an indole linker as a stable sequence-specific alkylating agent. In this study, we investigated the gene silencing ability of polyamides A, B and C, which potentially target specific sequences in the promoter region, noncoding strand, and coding strand of the green fluorescent protein (GFP) gene, resp. The GFP vectors were transfected into human colon carcinoma cells (HCT116), and the cells treated with 100 nM of the polyamides for 24 h. Using direct observation of cell by fluorescence microscopy, a significant GFP-gene silencing effect was only seen with treatment with polyamide C. Polyamides A and B did not show such activity.

865113-64-0 865113-67-3 885026-77-3
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(sequence-specific green fluorescent protein gene silencing in human

cells by alkylating Py-Im polyamide) 865113-64-0 CAPLUS

RN

CN

PAGE 3-A

RN 865113-67-3 CAPLUS

PAGE 3-A

ABBOS ABBOS



REFERENCE COUNT: 12 THERE ARE 12 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L11 ANSWER 7 OF 16 CAPLUS COPYRIGHT 2008 ACS on STN ACCESSION NUMBER: 2007:662158 CAPLUS Full-text

102a cross-over inventors

DOCUMENT NUMBER: 148:517913

TITLE: Molecular design of alkylating pyrrole-imidazole

polyamides with indole linker

AUTHOR(S): Sasaki, Shunta; Narita, Akihiko; Bando, Toshikazu; Sugiyama, Hiroshi

School of Biomedical Science, Tokyo Medical and Dental CORPORATE SOURCE: University, 2-3-10 Kanda-Surugadai, Chiyodaku, Tokyo,

101-0062, Japan

SOURCE: Nucleic Acids Symposium Series (2004), (48), 205-206

CODEN: NASSCJ

URL: http://nass.oxfordjournals.org/content/vol48/issu

e1/index.dtl

PUBLISHER: Oxford University Press

DOCUMENT TYPE: Journal; (online computer file) English

LANGUAGE:

AB A series of novel DNA alkylating polyamide possessing indole linker was synthesized. The reactivities and specificities of these polyamides with double strand DNA were investigated by using high-resoln. gel electrophoresis. The results revealed that the indole linker linked Py-Im polyamides have the high alkylating activities and sequence specificities comparable to vinyl linker linked Py-Im polyamides.

1021452-23-2P 1021452-26-5P 1021452-29-8P

1021452-32-39

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(mol. design of alkylating pyrrole-imidazole polyamides with indole

linker) RN 1021452-23-2 CAPLUS

CN INDEX NAME NOT YET ASSIGNED

Absolute stereochemistry.

PAGE 1-C



RN 1021452-26-5 CAPLUS

CN INDEX NAME NOT YET ASSIGNED

Absolute stereochemistry.

X

PAGE 1-C

RN 1021452-29-8 CAPLUS

CN INDEX NAME NOT YET ASSIGNED

Absolute stereochemistry.

PAGE 1-B

PAGE 1-C



RN 1021452-32-3 CAPLUS

CN INDEX NAME NOT YET ASSIGNED

Absolute stereochemistry.

PAGE 1-A

PAGE 1-B

PAGE 2-A



REFERENCE COUNT: 8 THERE ARE 8 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L11 ANSWER 8 OF 16 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2007:408268 CAPLUS Full-text

DOCUMENT NUMBER: 147:47403

TITLE: DNA Alkylation by Pyrrole-Imidazole seco-CBI

Conjugates with an Indole Linker: Sequence-Specific DNA Alkylation with 10-Base-Pair Recognition through

Heterodimer Formation

AUTHOR(S): Minoshima, Masafumi; Bando, Toshikazu; Sasaki, Shunta;

Shinohara, Ken-ichi; Shimizu, Tatsuhiko; Fujimoto,

Jun; Sugivama, Hiroshi

CORPORATE SOURCE: Department of Chemistry, Graduate School of Science
Kyoto University, Sakyo, Kyoto, 606-8502, Japan

SOURCE: Journal of the American Chemical Society (2007),

129(17), 5384-5390

CODEN: JACSAT; ISSN: 0002-7863

PUBLISHER: American Chemical Society

DOCUMENT TYPE: Journal LANGUAGE: English

OTHER SOURCE(S): CASREACT 147:47403

AB The sequence-specific DNA alkylation by onjugates 4 and 5, which consist of N-methylpyrrole (Py)-N-methylimidazolo (Im) polyamides and 1-(chloromethyl)-5-hydroxy-1,2-dihydro-3H-benz[e]indolo (seco-CBI) linked with an indole linker, was investigated in the absence of presence of partner Py-Im polyamide 6.
High-resoln. denaturing PAGE revealed that conjugate 4 alkylates DNA at the sequences 5'-(A/T)GCCTA-3' through hairpin formation, and alkylates 5'-GGAAAGAAAA-3' through an extended binding mode. However, in the presence of partner Py-Im polyamide 6, conjugate 4 alkylates DNA at a completely different sequence, 5'-AGGTTGTCCA-3'. Alkylation of 4 in the presence of 6 was effectively inhibited by a competitor 7. Surface plasmon resonance (SPR) results indicated that conjugate 4 does not bind to 5'-AGGTTGTCCA-3', whereas 6 binds tightly to this sequence. The results suggest that alkylation proceeds through heterodimer formation, indicating that this is a general way

to expand the recognition sequence for DNA alkylation by $\ensuremath{\mathsf{Py-Im}}$ seco-CBI conjugates.

IT 939435-69-5P 939435-70-8P

RL: BSU (Biological study, unclassified); PRP (Properties); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation) (sequence-specific DNA alkylation by pyrrole-imidazole seco-CBI conjugates with an indole linker)

RN 939435-69-5 CAPLUS

CN lH-Imidazole-2-carboxamide, 4-[[[4-(acetylamino)-1-methyl-1H-imidazol-2-yl]carbonyl]amino]-N-[5-[[3-[[3-[[2-[[[5-[1]c-[(15]-1-(chloromethyl)-1,2-dihydro-5-hydroxy-3H-benz [e]indol-3-yl]carbonyl]-1H-indol-5-yl]amino]carbonyl]-1-methyl-1H-pyrrol-3-yl]amino]carbonyl]-1-methyl-1H-imidazol-4-yl]amino]-3-oxopropyl]amino]carbonyl]-1-methyl-1H-pyrrol-3-yl]-1-methyl- (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A

PAGE 1-B

─ OH

RN 939435-70-8 CAPLUS

Absolute stereochemistry.

PAGE 1-B

PAGE 1-A

— он

REFERENCE COUNT:

37 THERE ARE 37 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L11 ANSWER 9 OF 16 CAPLUS COPYRIGHT 2008 ACS on STN ACCESSION NUMBER: 2006:860352 CAPLUS Full-text

DOCUMENT NUMBER: 145:448749

TITLE: Sequence-Specific Alkylation of Double-Strand Human

Telomere Repeat Sequence by Pyrrole-Imidazole

Polyamides with Indole Linkers

AUTHOR(S): Sasaki, Shunta; Bando, Toshikazu; Minoskima, Masafumi; Shimizu, Tatsuhiko; Shinohara, Ken-Ioki; Takaoka,

Toshiyasu; Sugiyama, Hiroshi

CORPORATE SOURCE: Department of Chemistry, Gradu

Department of Chemistry, Graduate School of Science,

Kyoto University, Kyoto, 606-8802, Japan

SOURCE: Journal of the American Chemical Society (2006),

128(37), 12162-12168

CODEN: JACSAT; ISSN: 0902-7863

PUBLISHER: American Chemical Society

DOCUMENT TYPE: Journal LANGUAGE: English

OTHER SOURCE(S): CASREACT 145:48749

GI

- * STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY AVAILABLE VIA OFFLINE PRINT *
- AB The authors designed and synthesized pyrrole (Py)-imidazole (Im) hairpin polyamide 1-(chloromethyl)-5-hydroxy-1,2-dihydro-3H-benz[e]indole (seco-CBI) conjugates which target both strands of the double-stranded region of the human telomere repeat sequences, 5'-d(TTAGGG)n-3',5'-d(CCCTAA)n-3'. Highresoln. denaturing PAGE demonstrated that the conjugates alkylated DNA at the 3' A of 5'-ACCCTA-3' and 5'-AGGGTTA-3', resp. Cytotoxicities of the conjugates were evaluated using 39 human cancer cell lines; avs. of log IC50 values for these conjugates were -6.96 (110 mM) and -7.24 (57.5 nM), resp. These conjugates have potential as antitumor drugs capable of targeting telomere repeat sequence.
- IT 865113-70-8P 912552-39-7P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(sequence-specific alkylation of double-strand human telomere repeat sequence by pyrrole-imidazole polyamides with indole linkers) $\,$

- RN 865113-70-8 CAPLUS
- CN 1H-Imidazole-2-carboxamide, 4-[[[4-(acetylamino)-1-methyl-1H-imidazol-2-

yl]carbonyl]amino]-N-[2-[[[4-[[5-[[[2-[1]-(chloromethyl)-1, 2-dihydro-5-hydroxy-3H-benz[e]indol-3-yl]carbonyl]-1H-indol-5-yl]amino]carbonyl]-1-methyl-1H-pyrrol-3-yl]amino]carbonyl]-1-methyl-1H-pyrrol-3-yl]amino]-doxobutyl]amino]carbonyl]-1-methyl-1H-imidazol-4-yl]-1-methyl- (CA INDEX NAME)



RN 912552-39-7 CAPLUS

CN 1H-Imidazole-2-carboxamide, 4-[[[4-[[4-[[4-[[4-[[4-[[4-[[4-[14-[caetylamino]-1-methyl-1H-pyrrol-2-y1]carbonyl]amino]-1-methyl-1H-pyrrol-2-y1]carbonyl]amino]-1-methyl-1H-pyrrol-2-y1]carbonyl]amino]-1-coxobutyl]amino]-1-methyl-1H-imidazol-2-y1]carbonyl]amino]-N-[2-[[[2-[[1-(chloromethyl)-1,2-dihydro-5-hydroxy-3H-benz[e]indol-3-y1]carbonyl]-1H-indol-5-y1]amino]carbonyl]-1-methyl-1H-imidazol-4-y1]-1-methyl- (CA INDEX NAME)

PAGE 1-A

PAGE 2-B

REFERENCE COUNT: 32 THERE ARE 32 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L11 ANSWER 10 OF 16 CAPLUS COPYRIGHT 2008 ACS on STN ACCESSION NUMBER: 2006:385992 CAPLUS <u>Full-text</u>

DOCUMENT NUMBER: 145:103905

TITLE: Efficient DNA Alkylation by a Pyrrole-Imidazole CBI Conjugate with an Indole Linker: Sequence-Specific

Alkylation with Nine-Base-Pair Recognition
AUTHOR(S): Bando, Toshikazu; Sasaki, Shunta; Minoshima, Ma

Bando, Toshikazu; Sasaki, Shunta; Minoshima, Masafumi; Dohno, Chikara; Shinohara, Ken-Ichi; Marita, Akihiko;

Sugiyama, Hiroshi

CORPORATE SOURCE: Department of Chemistry, Graduate School of Science, Kyoto University, Kyoto, 606-8501, Japan

SOURCE: Bioconjugate Chemistry (2006), 17(3), 715-720

CODEN: BCCHES; ISSN: 1043-1802

PUBLISHER: American Chemical Society

PUBLISHER: American Chemical Society
DOCUMENT TYPE: Journal

LANGUAGE: English

OTHER SOURCE(S): CASREACT 145:103905

- AB Conjugates of N-methylpyrrole (Py)-N-methylimidazole (Im) polyamides and 1,2,9,9a-tetrahydrocyclopropa[1,2-c]benz[1,2-c]indol-4-one (CBI) with a 5-amino-IH-indole-2-carbonyl linker were synthesized by Fmoc solid-phase synthesis and a subsequent liq.-phase coupling procedure. The DNA alkylating abilities of imidazole conjugates were examd. using Texas Red-labeld PCR fragments and high-resoln, denaturing gel electrophoresis. CBI conjugates exhibited highly efficient sequence-specific DNA alkylation comparable with previous CBI conjugates with a vinyl linker. Introduction of an indole linker greatly facilitated the synthesis of sequence-specific alkylating Py-Im polyamides.
- IT 865113-64-0P 865113-66-2P 865113-72-0P

893419-09-5P

CN

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(DNA alkylation by pyrrole-imidazole hydrocyclopropabenzindolone conjugate with indole linker and sequence-specific alkylation with nine-base-pair recognition)

RN 865113-64-0 CAPLUS

 $\begin{array}{ll} \text{H-Imidazole-2-carboxamide, } 4-[[[4-(acetylamino)-1-methyl-1H-imidazol-2-yl] carbonyl] amino]-N-[5-[[[5-[[[4-[[2-[[15-[[[2-[[9-y0-dhydro-4-oxo-1H-benzo[e] cycloprop[c] indol-2 (4H0-yl]-1H-imidalol-5-yl] amino] carbonyl]-1-methyl-1H-pyrrol-3-yl] amino] carbonyl]-1-methyl-1H-imidazol-4-yl] amino]-4-oxobutyl] amino] carbonyl]-1-methyl-1H-pyrrol-3-yl]-1-methyl-1H-pyrrol-3-yl]-1-methyl-1H-pyrrol-3-yl]-1-methyl-1H-pyrrol-3-yl]-1-methyl-1H-pyrrol-3-yl]-1-methyl-1H-pyrrol-3-yl]-1-methyl-1H-pyrrol-3-yl]-1-methyl-1H-pyrrol-3-yl]-1-methyl-1H-pyrrol-3-yl]-1-methyl-1H-pyrrol-3-yl]-1-methyl-1H-pyrrol-3-yl]-1-methyl-1H-pyrrol-3-yl]-1-methyl-1H-pyrrol-3-yl]-1-methyl-1H-pyrrol-3-yl]-1-methyl-1H-pyrrol-3-yl]-1-methyl-1H-pyrrol-3-yl]-1-methyl-1H-pyrrol-3-yl]-1-methyl-1H-pyrrol-3-yl]-1-methyl-1H-pyrrol-3-yl]-1-methyl-1H-pyrrol-3-yl]-1-methyl-1H-pyrrol-3-yl]-1-methyl-1H-pyrrol-3-yl]-1-methyl-1H-pyrrol-3-yl]-1-methyl-1H-pyrrol-3-yl]-1-methyl-1H-pyrrol-3-yl]-1-methyl-1H-pyrrol-3-yl]-1-methyl-1H-pyrrol-3-yl]-1-methyl-1H-pyrrol-3-yl]-1-methyl-1H-pyrrol-3-yl]-1-methyl-1H-pyrrol-3-yl]-1-methyl-1H-pyrrol-3-yl]-1-methyl-1H-pyrrol-3-yl]-1-methyl-1H-pyrrol-3-yl]-1-methyl-1H-pyrrol-3-yl]-1-methyl-1H-pyrrol-3-yl]-1-methyl-1H-pyrrol-3-yl]-1-methyl-1H-pyrrol-3-yl]-1-methyl-1H-pyrrol-3-yl]-1-methyl-1H-pyrrol-3-yl]-1-methyl-1H-pyrrol-3-yl]-1-methyl-1H-pyrrol-3-yl]-1-methyl-1H-pyrrol-3-yl]-1-methyl-1H-pyrrol-3-yl]-1-methyl-1H-pyrrol-3-yl]-1-methyl-1H-pyrrol-3-yl]-1-methyl-1H-pyrrol-3-yl]-1-methyl-1H-pyrrol-3-yl]-1-methyl-1H-pyrrol-3-yl]-1-methyl-1H-pyrrol-3-yl]-1-methyl-1H-pyrrol-3-yl]-1-methyl-1H-pyrrol-3-yl]-1-methyl-1H-pyrrol-3-yl]-1-methyl-1H-pyrrol-3-yl]-1-methyl-1H-pyrrol-3-yl]-1-methyl-1H-pyrrol-3-yl]-1-methyl-1H-pyrrol-3-yl]-1-methyl-1H-pyrrol-3-yl]-1-methyl-1H-pyrrol-3-yl]-1-methyl-1H-pyrrol-3-yl]-1-methyl-1H-pyrrol-3-yl]-1-methyl-1H-pyrrol-3-yl]-1-methyl-1H-pyrrol-3-yl]-1-methyl-1H-pyrrol-3-yl]-1-methyl-1H-pyrrol-3-yl]-1-methyl-1H-pyrrol-3-yl]-1-methyl-1H-pyrrol-3-yl]-1-methyl-1H-pyrrol-3-yl]-1-methyl-1H-pyrrol-3-yl]-1-methyl-1$

PAGE 3-A

RN 865113-66-2 CAPLUS

CN 1H-Imidazole-2-carboxamide, 4-(acetylamino)-N-[2-[[[5-[[[5-[[[4-[[5-[[5-[[[2-[[9,9a-dihydro-4-oxo-1H-benzo[e]cycloprop[c]indol-2(4H)-yl)carbonyl]-1 1H-indol-5-yl]amino]carbonyl]-1-methyl-1H-pyrrol-3-yl]amino]carbonyl]-1methyl-1H-pyrrol-3-yl]amino]-4-oxobutyl]amino]carbonyl]-1-methyl-1H-pyrrol-3-yl]amino]carbonyl]-1-methyl-1H-pyrrol-3-yl]amino]carbonyl]-1-methyl-1Himidazol-4-yl]-1-methyl-1 (CA INDEX NAME)

PAGE 2-A

PAGE 3-A

HH-Inidazole-2-carboxamide, 4-[[[4-(acetylamino)-1-methyl-1H-imidazol-2-yl]carbonyl]amino]-N-[5-[[[5-[[[4-[[2-[[[5-[[[2-[[1-c(hloromethyl)-1,2-dihydro-5-hydroxy-3H-benz [e]indol-3-yl]carbonyl]-1H-indol-5-yl]amino]carbonyl]-1-methyl-1H-pyrrol-3-yl]amino]carbonyl]-1-methyl-1H-imidazol-4-yl]amino]-4-oxobutyl]amino]carbonyl]-1-methyl-1H-pyrrol-3-yl]amino[carbonyl]-1-methyl-1H-pyrrol-3-yl]-1-methyl-1H-pyrrol-3-yl]-1-methyl-1H-pyrrol-3-yl]-1-methyl-1H-pyrrol-3-yl]-1-methyl-1H-pyrrol-3-yl]-1-methyl-1-[NEW]-NMEN)

PAGE 2-A

- 893419-09-5 CAPLUS RN
- CN 1H-Imidazole-2-carboxamide, 4-[[[4-(acetylamino)-1-methyl-1H-imidazol-2-[[[2-[[1-(chloromethy1)-1,2-dihydro-5-hydroxy-3H-benz[e]indol-3yl]carbonyl]-1H-indol-5-yl]amino]carbonyl]-1-methyl-1H-pyrrol-3-yl]amino]-3-oxopropyl]amino]carbonyl]-1-methyl-1H-pyrrol-3-yl]amino]carbonyl]-1methyl-1H-pyrrol-3-yl]amino]carbonyl]-1-methyl-1H-pyrrol-3-yl]amino]-4oxobutyl]amino]carbonyl]-1-methyl-1H-imidazol-4-yl]amino]carbonyl]-1methyl-1H-pyrrol-3-yl]amino]carbonyl]-1-methyl-1H-pyrrol-3-yl]amino]-3oxopropyl]amino]carbonyl]-1-methyl-1H-pyrrol-3-yl]-1-methyl- (CA INDEX NAME)

PAGE 1-A

PAGE 3-A

PAGE 5-A

27

REFERENCE COUNT:

THERE ARE 27 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

ACCESSION NUMBER: DOCUMENT NUMBER:

L11 ANSWER 11 OF 16 CAPLUS COPYRIGHT 2008 ACS on STN 2006:367591 CAPLUS Full-text 145:431752

TITLE:

Antitumor activity of sequence-specific alkylating agents: pyrolle-imidazole CBI conjugates with indole linker

AUTHOR(S):

Shinohara, Ken-ichi; Bando, Toshikazu; Sasaki, Shunta; Sakakibara, Yogo; Minoshima, Masafumi; Sugiyama,

CORPORATE SOURCE:

Department of Chemistry, Graduate School of Science, Kyoto University, Kitashirakawa-Oiwakecho, Sakyo,

Kyoto, 606-8502, Japan

Cancer Science (2006), 97(3), 219-225 CODEN: CSACCM; ISSN: 1347-9032

SOURCE:

PUBLISHER: Blackwell Publishing Asia Pty Ltd.

DOCUMENT TYPE: Journal LANGUAGE: English

AB

CN

DNA-targeting agents, including cisplatin, bleomycin and mitomycin C, are used routinely in cancer treatments. However, these drugs are extremely toxic, attacking normal cells and causing severe side effects. One important question to consider in designing anticancer agents is whether the introduction of sequence selectivity to DNA-targeting agents can improve their efficacy as anticancer agents. In the present study, the growth inhibition activities of an indole-seco 1,2,9,9a- tetrahydrocyclopropa[1,2-c]benz[1,2e]indol-4-one (CBI) (1) and five conjugates with hairpin pyrrole-imidazole polyamides (2-6), which have different sequence specificities for DNA alkylation, were compared using 10 different cell lines. The av. values of log GI50 (50% growth inhibition concn.) for compds. 1-6 against the 10 cell lines were 8.33, 8.56, 8.29, 8.04, 8.23 and 8.83, showing that all of these compds, strongly inhibit cell growth. Interestingly, each alkylating agent caused significantly different growth inhibition patterns with each cell line. In particular, the correlation coeffs. between the -log GI50 of compd. 1 and its conjugates 2-6 showed extremely low values (R < 0). These results suggest that differences in the sequence specificity of DNA alkylation lead to marked differences in biol. activity. Comparison of the correlation coeffs. between compds. 6 and 7, with the same sequence specificity as 6, and MS-247, with sequence specificity different from 6, when used against a panel of 37 human cancer cell lines further confirmed the above hypothesis.

IT 865113-64-0 865113-66-2 865113-67-3

885028-77-3 912572-04-4
RL: DMA (Drug mechanism of action); PAC (Pharmacological activity); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); USBS (Uses) (antitumor activity of pyrolle-imidazole CBI conjugates with indole linker)

RN 865113-64-0 CAPLUS

1H-Imidazole-2-carboxamide, 4-[[[4-(acetylamino)-1-methyl-1H-imidazol-2-yl]carbonyl]amino]-N-[5-[[[5-[[[4-[[2-[([5-[([2-[(9,9a-dihydro-4-oxo-1H-benzo[e]cycloprop[c]indol-2(4Ha)-yl]carbonyl]-1H-imidalol-5-yl]amino]carbonyl]-1-methyl-1H-pyrrol-3-yl]amino]carbonyl]-1-methyl-1H-imidazol-4-yl]amino]-4-oxobutyl]amino]carbonyl]-1-methyl-1H-pyrrol-3-yl]amino]carbonyl]-1-methyl-1H-pyrrol-3-yl]amino]carbonyl]-1-methyl-1H-pyrrol-3-yl]amino]carbonyl]-1-methyl-1H-pyrrol-3-yl]-1-methyl-1H-pyrrol-3-yl]-1-methyl-1H-pyrrol-3-yl]-1-methyl-1H-pyrrol-3-yl]-1-methyl-1H-pyrrol-3-yl]-1-methyl-1H-pyrrol-3-yl]-1-methyl-1H-pyrrol-3-yl]-1-methyl-1H-pyrrol-3-yl]-1-methyl-1H-pyrrol-3-yl]-1-methyl-1H-pyrrol-3-yl]-1-methyl-1H-pyrrol-3-yl]-1-methyl-1H-pyrrol-3-yl]-1-methyl-1H-pyrrol-3-yl]-1-methyl-1H-pyrrol-3-yl]-1-methyl-1H-pyrrol-3-yl]-1-methyl-1H-pyrrol-3-yl]-1-methyl-1H-pyrrol-3-yl]-1-methyl-1H-pyrrol-3-yl]-1-methyl-1H-pyrrol-3-yl]-1-methyl-1H-pyrrol-3-yl]-1-methyl-1H-pyrrol-3-yl]-1-methyl-1H-pyrrol-3-yl]-1-methyl-1H-pyrrol-3-yl]-1-methyl-1H-pyrrol-3-yl]-1-methyl-1H-pyrrol-3-yl]-1-methyl-1H-pyrrol-3-yl]-1-methyl-1H-pyrrol-3-yl]-1-methyl-1H-pyrrol-3-yl]-1-methyl-1H-pyrrol-3-yl]-1-methyl-1H-pyrrol-3-yl]-1-methyl-1H-pyrrol-3-yl]-1-methyl-1H-pyrrol-3-yl]-1-methyl-1H-pyrrol-3-yl]-1-methyl-1H-pyrrol-3-yl]-1-methyl-1H-pyrrol-3-yl]-1-methyl-1H-pyrrol-3-yl]-1-methyl-1H-pyrrol-3-yl]-1-methyl-1H-pyrrol-3-yl]-1-methyl-1H-pyrrol-3-yl]-1-methyl-1H-pyrrol-3-yl]-1-methyl-1H-pyrrol-3-yl]-1-methyl-1H-pyrrol-3-yl]-1-methyl-1H-pyrrol-3-yl]-1-methyl-1H-pyrrol-3-yl]-1-methyl-1H-pyrrol-3-yl]-1-methyl-1H-pyrrol-3-yl]-1-methyl-1H-pyrrol-3-yl]-1-methyl-1H-pyrrol-3-yl]-1-methyl-1H-pyrrol-3-yl]-1-methyl-1H-pyrrol-3-yl]-1-methyl-1H-pyrrol-3-yl]-1-methyl-1H-pyrrol-3-yl]-1-methyl-1H-pyrrol-3-yl]-1-methyl-1H-pyrrol-3-yl]-1-methyl-1H-pyrrol-3-yl]-1-methyl-1H-pyrrol-3-yl]-1-methyl-1H-pyrrol-3-yl]-1-methyl-1H-pyrrol-3-yl]-1-methyl-1H-pyrrol-3-yl]-1-methyl-1H-pyrrol-3-yl]-1-methyl-1H-pyrrol-3-yl]-1-methyl-1H-pyrrol-3-yl]-1-methyl-1H-pyrrol-3-yl]-1-methyl-1H-pyrrol-3-yl]-1-m

PAGE 3-A

RN 865113-66-2 CAPLUS

CN 1H-Imidazole-2-carboxamide, 4-(acetylamino)-N-[2-[[[5-[[[5-[[[5-[[[4-[[5-[[5-[[[2-[(9,9a-dihydro-4-oxo-1H-benzo[e]cycloprop(e]indol-2(4H)-y1)carbonyl]-1 1H-indol-5-y1]amino]carbonyl]-1-methyl-1H-pyrrol-3-y1]amino]carbonyl]-1methyl-1H-pyrrol-3-y1]amino]-4-oxobutyl]amino]carbonyl]-1-methyl-1H-pyrrol-3-y1]amino]carbonyl]-1-methyl-1H-pyrrol-3-y1]amino]carbonyl]-1-methyl-1Himidazol-4-y1]-1-methyl-1 (CA INDEX NAME)

PAGE 2-A

PAGE 3-A

RN 885028-77-3 CAPLUS

CN lH-Imidazole-2-carboxamide, 4-[[[4-(acetylamino)-1-methyl-1H-pyrrol-2-yl]carbonyl]amino]-N-[5-[[[5-[[[4-([2-([[5-([[2-([6,9a-dihydro-4-oxo-1H-benzo[e]gvcloprop[c]indol-2(4H)-yl]carbonyl]-1H-indol-5-yl]amino]carbonyl]-1-methyl-1H-pyrrol-3-yl]amino]carbonyl]-1-methyl-1H-imidazol-4-yl]amino]carbonyl]-1-methyl-1H-pyrrol-3-yl]amino]carbonyl]-1-methyl-1H-pyrrol-3-yl]-1-methyl-1CA INDEX NAME)

PAGE 1-A

PAGE 3-A

RN 912572-04-4 CAPLUS

PAGE 2-A

PAGE 3-A

L11 ANSWER 12 OF 16 CAPLUS COPYRIGHT 2008 ACS on STN ACCESSION NUMBER: 2006:207991 CAPLUS Full-text

19

DOCUMENT NUMBER: 144:426676

TITLE: Alkylation of template strand of coding region causes

effective gene silencing

AUTHOR(S): Shinohara, Ken-ichi; Sasaki, Shunta; Minoshima, Masafumi; Bando, Toshikazu; Sugiyama, Hiroshi

CORPORATE SOURCE: Department of Chemistry, Graduate School of Science,
Kyoto University, Kitashirakawa-Oiwakecho, Sakyo,

Kyoto, 606-8502, Japan

SOURCE: Nucleic Acids Research (2006), 34(4), 1189-1195

CODEN: NARHAD; ISSN: 03/05-1048
PUBLISHER: Oxford University Press

DOCUMENT TYPE: Journal LANGUAGE: English

AB We recently developed a new type of pyrrole (Py)-imidazole (Im) polyamide-tetrahydrocyclopropabenzindolone (CBI) conjugate with an indole linker as a stable sequence-specific alkylating agent. In this study, we investigated the gene silencing activities of polyamides A, B and C, which selectively alkylate specific sequences in the promoter region, non-coding strand and coding strand, resp., of the green fluorescent protein (GFP) gene. GFP vectors were transfected into human colon carcinoma cells (HCT116), and the cells were treated with 100 nM of the polyamides for 24 h. Fluorescence microscopy indicated that a significant redn of GFP fluorescence was only obsd. in the cells that were treated with polyamide C. In clear contrast, polyamides A and B did not show such activity. Moreover, real-time PCR demonstrated selective redn. of the expression of GFP mRNA following treatment with polyamide C. These results suggest that alkylating Py-Im polyamides that target the coding strand represent a novel approach for sequence-specific gene silencing.

I 865113-64-0 865113-67-3 885028-77-3
RI: BSU (Biological study, unclassified); BIOL (Biological study)
(alkylation and gene silencing by; alkylation of template strand of

coding region causes effective gene silencing)

RN 865113-64-0 CAPLUS

PAGE 2-A

PAGE 3-A

RN 885028-77-3 CAPLUS

CN lH-Imidazole-2-carboxamide, 4-[[[4-(acetylamino)-1-methyl-1H-pyrrol-2-yl]carbonyl]amino]-N-[5-[[[5-[[[4-([2-([[5-([[2-([6,9a-dihydro-4-oxo-1H-benzo[e]gvcloprop[c]indol-2(4H)-yl]carbonyl]-1H-indol-5-yl]amino]carbonyl]-1-methyl-1H-pyrrol-3-yl]amino]carbonyl]-1-methyl-1H-imidazol-4-yl]amino]carbonyl]-1-methyl-1H-pyrrol-3-yl]amino]carbonyl]-1-methyl-1H-pyrrol-3-yl]-1-methyl-1CA INDEX NAME)

PAGE 1-A

REFERENCE COUNT: 27 THERE ARE 27 CITED REFERENCES AVAILABLE FOR THIS
RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L11 ANSWER 13 OF 16 CAPLUS COPYRIGHT 2008 ACS on STN ACCESSION NUMBER: 2005:1026947 CAPLUS Full-text DOCUMENT NUMBER: 143:326365

TITLE: Preparation of indole derivatives for alkylating specific base sequence of DNA

INVENTOR(S): Sugiyama, Hiroshi; Bando, Toshikazu

PATENT ASSIGNEE(S): TMRC Co., Ltd., Japan SOURCE: PCT Int. Appl., 48 pp.

CODEN: PIXXD2
DOCUMENT TYPE: Patent

LANGUAGE: Japanese FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

| PATENT NO. | | | | | | KIN | D | DATE | | | APPL | ICAT | DATE | | | | | | | |
|---------------|--|----|-----|-----|-------------|-----|-----|------|----------------|-----|------|------|------|-----|-----|----------|-----|-----|--|--|
| | | | | | | | - | | | | | | | | | | | | | |
| WO 2005087762 | | | | | A1 20050922 | | | 0922 | WO 2005-JP4250 | | | | | | | 20050310 | | | | |
| | | W: | AE, | AG, | AL, | AM, | AT, | AU, | AZ, | BA, | BB, | BG, | BR, | BW, | BY, | BZ, | CA, | CH, | | |
| | | | CN, | CO. | CR. | CU. | CZ. | DE. | DK. | DM. | DZ. | EC. | EE. | EG. | ES, | FI. | GB. | GD. | | |

| | | | | | | | | | | | | | | ********* | *************************************** | *********** | | ******* |
|---------------|------|-----|------|-------|-----|------|------|-------|-----|------|------|------|-----|-----------|-----------------------------------------|-------------|-----|---------|
| | | | | | | | | | | | | | | | 1 | | | |
| | | GE, | GH, | GM, | HR, | HU, | ID, | IL, | IN, | IS, | JP, | KE, | KG, | KP, | ĶR, | KZ, | LC, | |
| | | LK, | LR, | LS, | LT, | LU, | LV, | MA, | MD, | MG, | MK, | MN, | MW, | MX, | /MZ, | NA, | NI, | |
| | | NO, | NZ, | OM, | PG, | PH, | PL, | PT, | RO, | RU, | SC, | SD, | SE, | SG, | SK, | SL, | SM, | |
| | | SY, | TJ, | TM, | TN, | TR, | TT, | TZ, | UA, | UG, | US, | UZ, | VC, | VN/ | YU, | ZA, | ZM, | zw |
| | RW: | BW, | GH, | GM, | KE, | LS, | MW, | MZ, | NA, | SD, | SL, | SZ, | TZ, | U¢, | ZM, | ZW, | AM, | |
| | | AZ. | BY. | KG. | KZ. | MD. | RU. | TJ, | TM. | AT. | BE. | BG. | CH. | dY. | CZ. | DE. | DK. | |
| | | EE, | ES, | FI, | FR. | GB, | GR, | HU, | IE, | IS, | IT, | LT, | LU, | MC. | NL, | PL, | PT, | |
| | | RO, | SE, | SI, | SK, | TR, | BF, | BJ, | CF. | CG, | CI, | CM, | GA, | /GN, | GO, | GW, | ML, | |
| | | MR. | NE, | SN. | TD. | TG | | | | | | | 1 | | | | | |
| AU 2005221959 | | | | | | | 2005 | 0922 | | AU 2 | 005- | 2219 | | 20050310 | | | | |
| EP 1731519 | | | | | A1 | | | | | | | | | 20050310 | | | | |
| | R: | AT. | | | | | | DE, | | | | | | GB. | | | | |
| | | | | | | | | NL, | | | | | | | | , | , | |
| CN | Α, | | | 0314 | | CN 2 | | | | , | | 0050 | 310 | | | | | |
| US | A1 | | | 0816 | | US 2 | | | | | | 0060 | | | | | | |
| KR | | | | 0221 | | KR 2 | | | | | | 0060 | | | | | | |
| | | | | 0420 | | IN 2 | | | | | | 0060 | | | | | | |
| PRIORIT | ** | | | 0.220 | | JP 2 | | | | | | 0040 | | | | | | |
| 111101111 | | | 1111 | • • | | | | | | WO 2 | | | | | | 0050 | | |
| OTHER S | MADI | חתם | 1/3. | 3263 | | 2 | 005- | 0. 42 | | | | 0000 | 040 | | | | | |
| GI | | | | | | · AI | 140. | 5205 | 0.5 | | | | | | | | | |
| G.T. | | | | | | | | | | | | | | | | | | |

- * STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY AVAILABLE VIA OFFLINE PRINT *
- AB Title compds. I [Rl = functional group alkylating DNA;; R2 = H, alkyl, acyl; X = II, etc.] were prepd. For example, EDCI mediated amidation of compd. III [R = 2-carboxyindol-5-ylamino], e.g., prepd. from III [R = OH] in 2 steps, with 1-(chloromethyl)-2,3-dihydro-lH-benz[e]indol-5-ol followed treatment with aq. NaHCO3 afforded compd. IV. In antitumor activity assays for 39 cancer cell lines (in vitro), the av. IC50 value of compd. IV was 100 nM. Compds. I are claimed useful as DNA alkylating agents.
- IT 965113-60-6P
 RI: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses) (prepn. of indole derivs. as DNA alkylating agents)
 RN 865113-60-6 CAPLUS
- RN 865113-60-6 CAPLUS
 RN 1H-Imidazole-2-carboxamide, 4-(acetylamino)-N-[2-[[[2-[[1-(chloromethyl)1,2-dihydro-5-hydroxy-3H-benz[e]indol-3-yl]carbonyl]-1H-indol-5yl]amino]carbonyl]-1-methyl-1H-imidazol-4-yl]-1-methyl- (CA INDEX NAME)

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(prepn. of indole derivs. as DNA alkylating agents)

RN 865113-61-7 CAPLUS

CN

CN

1H-Imidazole-2-carboxamide, 4-(acetylamino)-N-[2-[[[2-[(1a,2-dihydro-5-oxo-1H-benzo[e]cycloprop[c]indol-3(5H)-yl)carbonyl]-1H-indol-5yl]amino[carbonyl]-1-methyl-1H-imidazol-4-vl]-1-methyl- (CA INDEX NAME)

RN 865113-64-0 CAPLUS

 $\begin{array}{ll} 1H-Imidazole-2-carboxamide, & 4-[[[4-(acetylamino)-1-methyl-1H-imidazol-2-yl]carbonyl]amino]-M-[5-[[[5-([[4-([2-([15-([[2-([9-9a-dlhydro-4-oxo-1H-benzo[e]cycloprop[c]indol-2(4H)-yl]carbonyl]-1H-imidalol-5-yl]amino]carbonyl]-1-methyl-1H-pyrrol-3-yl]amino]carbonyl]-1-methyl-1H-imidazol-4-yl]amino]-4-oxobutyl]amino]carbonyl]-1-methyl-1H-pyrrol-3-yl]-1-methyl-1H-pyrrol-3-yl]-1-methyl-1H-pyrrol-3-yl]-1-methyl-1H-pyrrol-3-yl]-1-methyl-1H-pyrrol-3-yl]-1-methyl-1H-pyrrol-3-yl]-1-methyl-1H-pyrrol-3-yl]-1-methyl-1H-pyrrol-3-yl]-1-methyl-1H-pyrrol-3-yl]-1-methyl-1H-pyrrol-3-yl]-1-methyl-1H-pyrrol-3-yl]-1-methyl-1H-pyrrol-3-yl]-1-methyl-1H-pyrrol-3-yl]-1-methyl-1H-pyrrol-3-yl]-1-methyl-1H-pyrrol-3-yl]-1-methyl-1H-pyrrol-3-yl]-1-methyl-1H-pyrrol-3-yl]-1-methyl-1H-pyrrol-3-yl]-1-methyl-1H-pyrrol-3-yl]-1-methyl-1H-pyrrol-3-yl]-1-methyl-1H-pyrrol-3-yl]-1-methyl-1H-pyrrol-3-yl]-1-methyl-1H-pyrrol-3-yl]-1-methyl-1H-pyrrol-3-yl]-1-methyl-1H-pyrrol-3-yl]-1-methyl-1H-pyrrol-3-yl]-1-methyl-1H-pyrrol-3-yl]-1-methyl-1H-pyrrol-3-yl]-1-methyl-1H-pyrrol-3-yl]-1-methyl-1H-pyrrol-3-yl]-1-methyl-1H-pyrrol-3-yl]-1-methyl-1H-pyrrol-3-yl]-1-methyl-1H-pyrrol-3-yl]-1-methyl-1H-pyrrol-3-yl]-1-methyl-1H-pyrrol-3-yl]-1-methyl-1H-pyrrol-3-yl]-1-methyl-1H-pyrrol-3-yl]-1-methyl-1H-pyrrol-3-yl]-1-methyl-1H-pyrrol-3-yl]-1-methyl-1H-pyrrol-3-yl]-1-methyl-1H-pyrrol-3-yl]-1-methyl-1H-pyrrol-3-yl]-1-methyl-1H-pyrrol-3-yl]-1-methyl-1H-pyrrol-3-yl]-1-methyl-1H-pyrrol-3-yl]-1-methyl-1H-pyrrol-3-yl]-1-methyl-1H-pyrrol-3-yl]-1-methyl-1H-pyrrol-3-yl]-1-methyl-1H-pyrrol-3-yl]-1-methyl-1H-pyrrol-3-yl]-1-methyl-1H-pyrrol-3-yl]-1-methyl-1H-pyrrol-3-yl]-1-methyl-1H-pyrrol-3-yl]-1-methyl-1H-pyrrol-3-yl]-1-methyl-1H-pyrrol-3-yl]-1-methyl-1H-pyrrol-3-yl]-1-methyl-1H-pyrrol-3-yl]-1-methyl-1H-pyrrol-3-yl]-1-methyl-1H-pyrrol-3-yl]-1-methyl-1H-pyrrol-3-yl]-1-methyl-1H-pyrrol-3-yl]-1-methyl-1H-pyrrol-3-yl]-1-methyl-1H-pyrrol-3-yl]-1-methyl-1H-pyrrol-3-yl]-1-methyl-1H-pyrrol-3-yl]-1-methyl-1H-pyrrol-3-yl]-1-methyl-1H-pyrrol-3-yl]-1-methyl-1H-pyrrol-3-yl]-1-methyl-1H-p$

PAGE 3-A

RN 865113-65-1 CAPLUS

CN 1H-Imidazole-2-carboxamide, 4-[[4-(acetylamino)-1-methyl-1H-imidazol-2y1] carbonyl] amino]-N-[5-[[4-[[2-[[2-[(9,9a-dihydro-4-oxo-1H-benzo[e] cycloprop(c] indol-2(4H)-y1) carbonyl]-1H-indol-5-y1] amino] carbonyl]1-methyl-1H-imidazol-4-y1]amino]-4-oxobutyl]amino] carbonyl]-1-methyl-(CA INDEX NAME)

PAGE 1-A

PAGE 2-B

AcNH

RN 865113-66-2 CAPLUS CN 1H-Imidazole-2-carbo

PAGE 1-A

PAGE 3-A

RN 865113-67-3 CAPLUS

PAGE 2-A

PAGE 3-A

CN

1H-Imidazole-2-carboxamide, 4-[[[4-(acetylamino)-1-methyl-1H-imidazol-2y1]carbony1]amino]-N-[5-[[[5-[[[3-[[5-[[[5-[[[4-[[2-[[[5-[[[5-[[[5-[[[2-[(9,9a-dihydro-4-oxo-1H-benzo[e]cycloprop[c]indo1-2(4H)-y1)carbony1]-1H-indol-5-vl]amino|carbonvl|-1-methyl-1H-pyrrol-3-vl|amino|carbonvl|-1methyl-1H-imidazol-4-yl]amino]-3-oxopropyl]amino]carbonyl]-1-methyl-1Hpyrrol-3-yl]amino]carbonyl]-1-methyl-1H-imidazol-4-yl]amino]-4oxobutyl]amino]carbonyl]-1-methyl-1H-pyrrol-3-yl]amino]carbonyl]-1-methyl-1H-pyrrol-3-yl]amino]-3-oxopropyl]amino]carbonyl]-1-methyl-1H-pyrrol-3yl]amino]carbonyl]-1-methyl-1H-pyrrol-3-yl]-1-methyl- (9CI) (CA INDEX NAME)

PAGE 2-A

PAGE 4-A

RN 865113-69-5 CAPLUS

CN 1H-Imidazole-2-carboxamide, 4-[[[4-(acetylamino)-1-methyl-1H-imidazol-2-yl]carbonyl]amino]-N-[5-[[[3-[[2-[[1]-[[0]-q-dihydro-4-oxo-1H-benzo[e]cycloprop[c]indol-2(4H)-yl] carbonyl]-1H-indol-5-yl]amino]carbonyl]-1-methyl-1H-pyrrol-3-yl]amino]carbonyl]-1-methyl-1H-imidazol-4-yl]amino]-3-oxopropyl]amino]carbonyl]-1-methyl-1H-pyrrol-3-yl]-1-methyl- (CA INDEX NAME)

PAGE 1-A

RN 865113-70-8 CAPLUS

CN 1H-Imidazole-2-carboxamide, 4-[[[4-(acetylamino)-1-methyl-1H-imidazol-2-yl]carbonyl]amino]-N-[2-[[4-[[5-[[[5-[[[2-[[1-(chloromethyl)-1,2-dihydro-5-hydroxy-3H-benz [e]indol-3-yl]carbonyl]-1H-imidazol-5-yl]amino]carbonyl]-1-methyl-1H-pyrrol-3-yl]amino]-4-oxobutyl]amino]carbonyl]-1-methyl-1H-imidazol-4-yl]-1-methyl- (CA INDEX NAME)

PAGE 1-A

PAGE 2-A

PAGE 3-A

IT 865113-72-0

RI: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses) (prepn. of indole derivs. as DNA alkylating agents)

RN 865113-72-0 CAPLUS

CN 1H-Imidazole-2-carboxamide, 4-[[[4-(acetylamino)-1-methyl-1H-imidazol-2-yl]carbonyl]amino]-N-[5-[[[5-[[[4-[[2-[[12-[[12-[[1-(chloromethyl)-1,2-dihydro-5-hydroxy-3H-benz [e]indol-3-yl]amino]-arbonyl]-1H-indol-5-yl]amino]carbonyl]-1-methyl-1H-pyrrol-3-yl]amino]carbonyl]-1-methyl-1H-jmidazol-4-yl]amino]-arbonyl]-1-methyl-1H-pyrrol-3-yl]amino]carbonyl]-1-methyl-1H-pyrrol-3-yl]amino]carbonyl]-1-methyl-1H-pyrrol-3-yl]amino]carbonyl]-1-methyl-1H-pyrrol-3-yl]amino]carbonyl]-1-methyl-1H-pyrrol-3-yl]amino]carbonyl]-1-methyl-1H-pyrrol-3-yl]amino]carbonyl]-1-methyl-1H-pyrrol-3-yl]amino]carbonyl]-1-methyl-1H-pyrrol-3-yl]amino]carbonyl]-1-methyl-1H-pyrrol-3-yl]amino]carbonyl]-1-methyl-1H-pyrrol-3-yl]amino]carbonyl]-1-methyl-1H-pyrrol-3-yl]amino]carbonyl]-1-methyl-1H-pyrrol-3-yl]amino]carbonyl]-1-methyl-1H-pyrrol-3-yl]amino]carbonyl]-1-methyl-1H-pyrrol-3-yl]amino]carbonyl]-1-methyl-1H-pyrrol-3-yl]amino]carbonyl]-1-methyl-1H-pyrrol-3-yl]amino]carbonyl]-1-methyl-1H-pyrrol-3-yl]amino]carbonyl]-1-methyl-1H-pyrrol-3-yl]amino]carbonyl]-1-methyl-1H-pyrrol-3-yl]amino]carbonyl]-1-methyl-1H-pyrrol-3-yl]-1-methyl-1H-pyrrol-3-yl]-1-methyl-1H-pyrrol-3-yl]-1-methyl-1H-pyrrol-3-yl]-1-methyl-1H-pyrrol-3-yl]-1-methyl-1H-pyrrol-3-yl]-1-methyl-1H-pyrrol-3-yl]-1-methyl-1H-pyrrol-3-yl]-1-methyl-1H-pyrrol-3-yl]-1-methyl-1H-pyrrol-3-yl]-1-methyl-1H-pyrrol-3-yl]-1-methyl-1H-pyrrol-3-yl]-1-methyl-1H-pyrrol-3-yl]-1-methyl-1H-pyrrol-3-yl]-1-methyl-1H-pyrrol-3-yl]-1-methyl-1H-pyrrol-3-yl]-1-methyl-1H-pyrrol-3-yl]-1-methyl-1H-pyrrol-3-yl]-1-methyl-1H-pyrrol-3-yl]-1-methyl-1H-pyrrol-3-yl]-1-methyl-1H-pyrrol-3-yl]-1-methyl-1H-pyrrol-3-yl]-1-methyl-1H-pyrrol-3-yl]-1-methyl-1H-pyrrol-3-yl]-1-methyl-1H-pyrrol-3-yl]-1-methyl-1H-pyrrol-3-yl]-1-methyl-1H-pyrrol-3-yl]-1-methyl-1H-pyrrol-3-yl]-1-methyl-1H-pyrrol-3-yl]-1-methyl-1H-pyrrol-3-yl]-1-methyl-1H-pyrrol-3-yl]-1-methyl-1H-pyrrol-3-yl]-1-methyl-1H-pyrrol-3-yl]-1-methyl-1H-pyrrol-3-yl]-1-methyl-1H-pyrrol-3-yl]-1-methyl-1H-pyrrol-3-yl]-1-methyl-1-methyl-1-methyl-1-methyl-1-methyl-1-methyl-1-methyl-1-methyl-

PAGE 1-A

PAGE 2-A



REFERENCE COUNT: 41 THERE ARE 41 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L11 ANSWER 14 OF 16 CAPLUS COPYRIGHT 2008 ACS on STN ACCESSION NUMBER: 2003:696700 CAPLUS Full-text

139:219341 DOCUMENT NUMBER:

TITLE: DNA-binding amide-drug conjugates

INVENTOR(S): Szekely, Zoltan; Hariprakasha, Humcha Krishnamurthy; Cholody, Marek W.; Michejda, Christopher J.

PATENT ASSIGNEE(S): The Government of the United States of America.

Represented by the Secretary Department of Health and

Human Services, USA PCT Int. Appl., 50 pp. SOURCE:

CODEN: PIXXD2

DOCUMENT TYPE: Patent LANGUAGE: English

FAMILY ACC. NUM. COUNT:

PATE

| PATENT INFORMATION: | **102b** | | | | | | | | | |
|--------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------|--|--|--|--|--|--|--|--|
| PATENT NO. | KIND DATE APPLICATION NO. | DATE | | | | | | | | |
| WO 2003072058
WO 2003072058 | A2 20030904 WO 2003-US6006
A3 20040805 | 20030227 | | | | | | | | |
| M: AE, AG, AL, CO, CR, CU, GM, HR, HU, LS, LT, LU, PL, PT, RO, UA, UG, US, RW: GH, GM, KE, KG, KZ, MD, | AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LV, MA, MD, MG, MK, NN, MW, MX, MZ, NO RU, SC, SD, SE, SG, SK, SL, IJ, TM, TN UZ, VC, VN, YU, ZA, ZM, ZW LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE | , GD, GE, GH,
, LC, LK, LR,
, NZ, OM, PH,
, TR, TT, TZ,
, AM, AZ, BY,
, DK, EE, ES, | | | | | | | | |
| BJ, CF, CG,
AU 2003217782 | GR, HU, IE, IT, LU, MC, NL, PT, SE, SI
CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN
A1 20030909 AU 2003-217782 | , TD, TG
20030227 | | | | | | | | |
| US 20050096261
PRIORITY APPLN. INFO.: | A1 20050505 US 2004-506085
US 2002-361050P
US 2002-370168P
WO 2003-US6006 | P 20020405 | | | | | | | | |

MARPAT 139:219341 OTHER SOURCE(S):

AB An amide conjugate comprising a DNA intercalator binds to the minor groove of DNA. A compn. comprising the conjugate and a carrier is useful for treating cancer in a mammal. Thus, 1-(chloromethyl)-5-hydroxy-1,2-dihydro- 3H-

benz[e]indole-8-carboxylic acid (CBIr), a rigid DNA alkylator, was prepd. and conjugated to an imidazole-contq. deriv.

IT 591246-21-4 591248-24-7
RI: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(DNA-binding polyamide drug conjugates)

N 591248-21-4 CAPLUS

CN

1H-Benz[e]indole-8-carboxamide, 1-(chloromethyl)-N-[2-[[2-[[2-[[2-[[3-([dimethylamino)propyl]amino]carbonyl]-1-methyl-1H-imidazol-4-yl]amino]carbonyl]-1-methyl-1H-imidazol-4-yl]amino]carbonyl]-1-methyl-1H-imidazol-4-yl]amino]carbonyl]-1-methyl-1H-imidazol-4-yl]-2,3-dihydro-5-hydroxy-3-[5-[[1-methyl-4-[1-oxo-3-[15-4]3-[6-oxo-6H-imidazol-5,1-d-3-4]3-[6-oxo-6H-imidazol-5]-1]-diplerational discounting the second sec

PAGE 1-A

RN 591248-24-7 CAPLUS

CN 5,12-Naphthacenedione, 10-[[3-[[4-[[5-[[12-[[1-(chloromethyl)]-8-[2-[[5-[[12-([1-(chloromethyl)]-1,2-dihydro-5-hydroxy-8-[[[1-methyl-5-[[[1-methyl-2-[[13-[4-[3-[[6-oxo-6H-imidazo[4,5,1-de]acridin-5-yl)amino]propyl]-1-piperazinyl]propyl]amino]carbonyl]-1H-imidazol-4-yl]amino]carbonyl]-1H-pyrrol-3-yl]amino]carbonyl]-3H-bane [elindol-3-yl]carbonyl]-1H-imidol-5-yl]amino]carbonyl]-4-hydroxy-1-methyl-1H-pyrrol-3-yl]amino]-2-oxoethyl]-1,2-dihydro-5-hydroxy-3H-penz [elindol-3-yl]carbonyl]-1H-indol-5-yl]amino]carbonyl]-1-methyl-1H-pyrrol-3-yl]amino]-4-oxobutyl]amino]-2,3,6-trideoxy-.alpha.-L-lyxo-hexopyranosyl]oxy]-7,8,9,10-tetrahydro-6,8,11-trihydroxy-8-(hydroxy-3c-yl)-1-methyl-1(s)-(S)-(S)-(S)-(S)-(CA-NDEX-NAME)

Absolute stereochemistry.

PAGE 1-A

PAGE 1-C

PAGE 1-D

L11 ANSWER 15 OF 16 CAPLUS COPYRIGHT 2008 ACS on STN ACCESSION NUMBER: 2003:221652 CAPLUS Full-text

DOCUMENT NUMBER: TITLE:

PATENT ASSIGNEE(S):

138:255007

INVENTOR(S):

SOURCE:

GI

Preparation of CBI analogues of CC 1065 and the duocarmycins for therapeutic use as anticancer agents Boger, Dale L.

The Scripps Research Institute, USA PCT Int. Appl., 35 pp. CODEN: PIXXD2

DOCUMENT TYPE:

Patent LANGUAGE: English FAMILY ACC. NUM. COUNT: 1

cited 103a **gone**

| PATENT I | | | | NI: | 1 | | | | | | | | | | | | |
|---------------|-------|-------|-----------|-----|------|-----------------|------|------|-----------------|----|-------|------|-----|----------|-----|------|-----|
| PATENT NO. | | | KAND DATE | | | APPLICATION NO. | | | | | | DATE | | | | | |
| WO 2003022806 | | | / | A2 | | 20030320 | | | WO 2002-US28749 | | | | | 20020909 | | | |
| WO | 20031 | 02281 | Merrin, | _ | A3 | | 2003 | 1113 | | | | | | | | | |
| | W: | ΑE, | AG, | AL, | AM, | AT, | AU, | ΑZ, | BA, | BE | BG, | BR, | BY, | ΒZ, | CA, | CH, | CN, |
| | | co, | CR, | CU, | CZ, | DE, | DK, | DM, | DZ, | EC | EE, | ES, | FΙ, | GB, | GD, | GE, | GH, |
| | | | | | | | | | | | , KG, | | | | | | |
| | | | | | | | | | | | , MW, | | | | | | |
| | | | | | | | | | | | , SL, | ТJ, | TM, | TN, | TR, | TT, | TZ, |
| | | | | | | | YU, | | | | | | | | | | |
| | RW: | | | | | | | | | | , TZ, | | | | | | |
| | | | | | | | | | | | , CH, | | | | | | |
| | | | | | | | | | | | , PT, | | | | | ВJ, | CF, |
| | | | | CM, | | | | | | | , NE, | | | | | | |
| | 24593 | | | | | | | | | | 2002- | | | | | | |
| | | | | | | | | | | | 2002- | | | | | | |
| EP | | | | | | | | | | | 2002- | | | | | | |
| | R: | | | | | | | | | | , IT, | | | | | MC, | PT, |
| | | | | | | | | | | | , TR, | | | | | | |
| | | | | | | | | | | | 2003- | | | | | | |
| | | | | | A1 | | 2005 | 0120 | | | 2004- | | | | | 0040 | |
| PRIORITY | APPI | LN. : | INFO | . : | | | | | | | 2001- | | | | | | |
| | | | | | | | | | 0.77 | WO | 2002- | US28 | 749 | | W 2 | 0020 | 909 |
| OTHER SO | URCE | (5): | | | MARI | PAT | 138: | 2550 | U / | | | | | | | | |

Ι

N — CO - X — NH - CO - Y — NH - CO2CMe3

AB 132 CBI analogs I IX, Y = arylene, heteroarylene] of CC 1065 and the duocarmycins having dimeric monocyclic, bicyclic, and tricyclic heteroaroms. substituents were synthesized by a parallel route. The resultant analogs were evaluated with respect to their catalytic and cytotoxic activities. The relative contribution of the various dimeric monocyclic, bicyclic, and tricyclic heteroaroms. Substituents within the DNA binding domain were characterized. Several of the resultant CBI analogs of CC 1065 and the duocarmycins were characterized as having enhanced catalytic and cytotoxic activities and were identified as having utility as anti-cancer agents. Thus, I (X = Y = -4-C6H4-) was prepd. starting from 4-H2NC6H4CO2H and the hydrochloride salt of seco-CBI.

T 372954-19-3P 372954-20-6P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(synthesis and evaluation of tetrahydrocyclopropa[c]benz[e]indol-4-one analogs of CC-1065 and the duocarmycins defining the contribution of the DNA-binding domain)

RN 372954-19-3 CAPLUS

CN Carbamic acid, [2-[[[2-[[(1S)-1-(chloromethy1)-1,2-dihydro-5-hydroxy-3H-benz[e]indol-3-yl]carbonyl]-1H-indol-5-yl]amino|carbonyl]-1-methyl-1H-inidazol-4-yl]-, 1,1-dimethylethyl ester (9C1) (CA INDEX NAME)

Absolute stereochemistry.

RN 372954-20-6 CAPLUS

CN Carbamic acid, [5-[[2-[(18)-1-(chloromethyl)-1,2-dihydro-5-hydroxy-3H-benz[e]indol-3-yl]carbonyl]-1H-indol-5-yl]amino[carbonyl]-1-methyl-1H-pyrrol-3-yl]-, 1,1-dimethylethyl ester (901) (CA INDEX NAME)

Absolute stereochemistry.

L11 ANSWER 16 OF 16 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2001:667407 CAPLUS Full-text

DOCUMENT NUMBER: 135:357786

TITLE: Parallel Synthesis and Evaluation of 132

(+)-1,2,9,9a-Tetrahydrocyclopropa[c]benz[e]indol-4-one (CBI) Analogues of CC-1065 and the Duocarmycins Defining the Contribution of the DNA-Binding Domain

Boger, Dale L.; Schmitt, Harald W.; Fink, Brian E.; AUTHOR(S):

Hedrick, Michael P.

Department of Chemistry and The Skaggs Institute for CORPORATE SOURCE: Chemical Biology, The Scripps Research Institute, La

Jolla, CA, 92037, USA

SOURCE: Journal of Organic Chemistry (2001), 66(20), 6654-6661

CODEN: JOCEAH; ISSN: 0022-3263

PUBLISHER: American Chemical Society DOCUMENT TYPE: Journal

LANGUAGE: English

OTHER SOURCE(S): CASREACT 135:357786

The soln.-phase, parallel synthesis and evaluation of a library of 132 (+)-1,2,9,9a-tetrahydrocyclopropa[c]benz[e]indol-4-one (CBI) analogs of CC-1065 and the duocarmycins contg. dimeric monocyclic, bicyclic, and tricyclic heteroarom, replacements for the DNA-binding domain are described. This systematic study revealed clear trends in the structural requirements for observation of potent cytotoxic activity and DNA alkylation efficiency, the range of which spans a magnitude of .gtoreq.10 000-fold. Combined with related studies, these results highlight that the role of the DNA-binding domain goes beyond simply providing DNA-binding selectivity and affinity (10-100-fold enhancement in properties), consistent with the proposal that it contributes significantly to catalysis of the DNA alkylation reaction accounting for as much as an addnl. 1000-fold enhancement in properties.


TT 372954-19-3P 372954-20-6P

RL: ADV (Adverse effect, including toxicity); BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation) (synthesis and evaluation of tetrahydrocyclopropa[c]benz[e]indol-4-one analogs of CC-1065 and the duocarmycins defining the contribution of the DNA-binding domain)

RN 372954-19-3 CAPLUS

CN Carbamic acid, [2-[[[2-[[(1S)-1-(chloromethyl)-1,2-dihydro-5-hydroxy-3Hbenz[e]indol-3-yl]carbonyl]-1H-indol-5-yl]amino]carbonyl]-1-methyl-1Himidazol-4-vl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



372954-20-6 CAPLUS RN

CN Carbamic acid, [5-[[[2-[[(1S)-1-(chloromethy1)-1,2-dihydro-5-hydroxy-3Hbenz[e]indol-3-v1]carbonv1]-1H-indol-5-v1]amino]carbonv1]-1-methv1-1Hpyrrol-3-yl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

REFERENCE COUNT: 61 THERE ARE 61 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

=>

=>
Executing the logoff script...

=> LOG H

| COST IN U.S. DOLLARS | SINCE FILE | TOTAL |
|--------------------------------------------|-----------------|-------------------|
| FULL ESTIMATED COST | ENTRY
92.96 | SESSION
520.51 |
| DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS) | SINCE FILE | TOTAL |
| CA SUBSCRIBER PRICE | ENTRY
-12.80 | SESSION
-20.00 |

SESSION WILL BE HELD FOR 120 MINUTES STN INTERNATIONAL SESSION SUSPENDED AT 21:44:28 ON 08 JUL 2008